Medications List

Prepared for NHS Connecting for Health Version 1.0.0.0 Baseline Prepared by Clinical Applications and Patient Safety Project NHS CUI Programme Team Cuistakeholder.mailbox@hscic.gov.uk

PREFACE

PREFACE
1 INTRODUCTION
2 GUIDANCE OVERVIEW
- 2.1 Summary of Guidance
3 GUIDANCE DETAILS
4 DOCUMENT INFORMATION
APPENDIX A REFERENCE SUMMARY OF GUIDANCE
REVISION AND SIGNOFF SHEET

Source PDF: medlist.pdf

Documents replaced by this document Design Guide Entry – Medications Management – Medication Views 2.0.0.0 Documents to be read in conjunction with this document Medications Management – Medication Line – User Interface Design Guidance 2.0.0.0 Design Guide Entry – Patient Banner 3.0.0.0 Displaying Graphs and Tables – User Interface Design Guidance 2.0.0.0 Patient Safety Process The development cycle for this design guide is compliant with the Clinical Safety Management System (CSMS) – the patient safety risk assessment and management process defined by NHS Connecting for Health (NHS CFH) in conjunction with the National Patient Safety Agency (NPSA). The design guide developers reviewed patient safety incidents arising from both current practice and existing systems for medications management. The resulting guidance points support mitigation of these known patient safety risks. In addition, the developers identified any potential new risks by applying a patient-safety risk-assessment process. The developers are assessing and managing all risks to support a Clinical Safety Case for this design guide. The Hazard Log records all hazards and risks raised to date and includes mitigation actions that, in some cases, will be applicable to you if you are an implementer or other user of this design guide. The Hazard Log is a live document and updates regularly whilst this design guide continues its development. Until this design guide has received full Clinical Authority to Release (CATR) from the NHS CFH Clinical Safety Group (CSG) – based on an approved Clinical Safety Case – there may be outstanding patient safety risks yet to be identified and mitigated. Therefore, it is essential that you review the relevant Hazard Log in conjunction with this design guide. Refer to nww.cui.nhs.uk (N3 connection required) for all current patient safety documentation, including Hazard Logs and the current patient safety process status for this and other design guides. This document was prepared for NHS Connecting for Health which ceased to exist on 31 March 2013. It may contain references to organisations, projects and other initiatives which also no longer exist. If you have any questions relating to any such references, or to any other aspect of the content, please contact cuistakeholder.mailbox@hscic.gov.uk

1 INTRODUCTION

This document provides guidance for the display of a list of medications for one patient in a user interface (UI). It describes what is meant by a list of medications, defines the scope, lists mandatory and recommended guidance points with usage examples and explains the rationale behind the guidance.

This document replaces the previously published guidance Medications Management – Medication Views {R1} . A significant number of the changes to the guidance are designed to allow flexibility and encourage innovation. The guidance has been amended to ensure that it is relevant to lists of medications that may have different structures and content and it has been extended to provide specific guidance where a standard is needed to mitigate patient safety hazards.

Table 1 describes the changes made since the previous version of this guidance (Baseline version 2.0.0.0 dated 12-Oct-2008):

Deleted MEDv-001 to MEDv-015

MEDv-016 to MEDv-018

Deleted to remove constraints that relate to specific views other than a medication list, navigation between views and guidance relating to a framework of views

Removed because they are general versions of the more specific guidance in the sections on Current and Past (MEDv-063), Past Filters (MEDv-066) and Grouping (MEDv-084) respectively

MEDv-019 Removed as further research is being carried out that may inform the production of guidance for the display of and navigation between different sets of medications information (Levels of Detail)

MEDv-033 Removed because decision support alerts need to be considered as part of a larger framework

MEDv-034 MEDv-040

Superseded by more detailed guidance in Medications Management – Medication Line {R2} guidance document, section 3.3.4

MEDv-039 Replaced by MEDi-001 in Medications Management – Medication Line {R2} guidance document

MEDv-041 Replaced by MEDi-018 in Medications Management – Medication Line {R2} guidance document

MEDv-026 Removed because the formatting defined in MEDv-024 and MEDv-025 is sufficient to distinguish medications with a different status

MEDv-046 Replaced by MEDv-179, MEDv-180 and MEDv-181 as the look-ahead scroll bar (LASB) is now displayed in a reserved space

MEDv-047 Replaced by the more specific MEDv-181

MEDv-057 Deleted because medication lines are no longer shown within a recent past notification

MEDv-060 MEDv-061

Superseded by MEDv-182 because the LASB is no longer recommended as a navigation tool

MEDv-073 Removed because this is covered by MEDv-068

MEDv-076 MEDv-078 to MEDv-082

Removed to mitigate UI design and technical issues associated with the display of recent past medications within the current medications list

MEDv-088 Removed to allow the user to control the grouping and group states (expanded or collapsed) in each of Current and Past medications respectively and independently

MEDv-093 to MEDv-098

Relate to the duplication of medications that belong in more than one group. Removed as this approach is no longer recommended since guidance cannot effectively mitigate the risks that it has been found to introduce.

MEDv-106 This sorting restriction (do not allow sorting by hidden attributes) has been removed to allow the provision of mechanisms that can support sorting other than by clicking on visible column headings

MEDv-107 to Relate to the control and display of Levels of Detail. Removed because guidance can only assess risks by

Page 1

HSCIC Controlled Document

rather than extending it, we hope to encourage innovation in this area

MEDv-134 Removed to avoid the implication that the context menu should be used to display information about the selected medications

MEDv-137 to MEDv-140

Relate to display of detailed information about a single medication. These guidance points have been removed because further work is needed to identify guidance in this area. If all details for one medication are displayed in such a way that occludes the information in the list, there is a risk that the partially visible medications information may be used to inform clinical judgement. This risk needs further assessment and further design exploration is needed to explore the provision of information without occluding the medications in the list. These risks are best addressed as part of a more comprehensive design for the display of all details for one medication.

Modified MEDv-020 Rephrased and extended to clarify that each line represents one medication

MEDv-025 Rephrased to remove the potential for it to be interpreted as supporting the display of current and past medications concurrently in the same list

MEDv-028 to MEDv-032 MEDv-034 to MEDv-038

Replaced with new guidance that is provides principles for the ordering and formatting of columns and for wrapping rather than requiring the display of specific columns in a set order

MEDv-049 Rephrased to clarify that the order of drugs in the look-ahead notifications must be consistent with the order of medications in the list

MEDv-056 Rephrased to clarify that the black dot in the look-ahead scroll bar notifications should have a space either side

MEDv-067 Rephrased to clarify that a ‘show all past’ (or equivalent) option should be available in the list of filters for past medications

MEDv-068 Rephrased to differentiate it from MEDv-070 and to clarify that it refers specifically to the presence and location of a control for removing a filter

MEDv-072 Conformance rating changed from Mandatory to Recommended to allow for brevity in filter notification messages

MEDv-083 Conformance rating changed from Mandatory to Recommended to allow for the default presentation of grouping to support users focused solely on a specific task

MEDv-084 Rephrased to replace to ‘combo-box’ with the more accurate ‘drop-down box’

MEDv-089 Changed so that it only requires counts to be shown in group headings for groups that are collapsed

MEDv-090 Conformance rating changed from mandatory to recommended in order to allow for the display of group headings for empty groups when the grouping scheme has few groups and is used for specific tasks that require explicit confirmation of empty groups

MEDv-099 MEDv-100

Rephrased to clarify that ‘start date’ and ‘end date’ are not necessarily the correct definitions or column labels for the dates to which the default sorts are applied

MEDv-103 Conformance rating changed from Mandatory to Recommended since it is supplementary to the use of an icon to indicate the sort order in a column heading

MEDv-104 Rephrased to clarify that a text symbol such as a triangle could be used instead of an icon

MEDv-105 Rephrased to refer to the default sort rather than reference an explicit sort order

MEDv-127 Extended to describe the keyboard shortcuts explicitly

MEDv-022 MEDv-059 MEDv-064 MEDv-074

Wording revised for clarity, without altering the meaning

Page 2

HSCIC Controlled Document

Added MEDv-141 to MEDv-201

These guidance points have been added

Table 1: Changes Since the Last Baseline Version

Note

In this document, the words ‘generic’ and ‘brand’, when associated with drug names, are used with very specific meanings that may differ from their accepted meanings in other contexts. Refer to section 4.2 for definitions of the specific terminology used in this document.

1.1 Customer Need

An electronic system for managing a patient’s medications must be able to support the complex needs of a wide range of health care professions and health care settings. A successful display solution must therefore balance those complex information needs with safety concerns, and ensure consistency across views and between systems.

Medications Incidents - The National Patient Safety Agency (NPSA) reports that the majority of medication incidents reported between January 2005 and June 2006 (59,802 in total) related to the administration of medicines (59.3 percent), followed by incidents related to the preparation and dispensing of medications (17.8 percent) and the prescribing of medications (15.7 percent). Their findings, documented in Safety in doses: medication safety incidents in the NHS [1], also state that the most common types of medication incidents reported to the NSPA included incorrect dose, incorrect strength or frequency, omitted medicine and wrong medicine.

Existing Systems - In-patient hospital care settings currently use multiple kinds of medications documents, both paper-based and electronic. As care professionals move between hospitals and are faced with new information groupings while working in stressful environments, the differences in the designs of the documents they use may well already impact patient safety. Differences in display formats for medicines impact both the review and management of those medications and will become a safety concern as electronic systems become more widely available in the next few years. The challenge for designers developing electronic systems in this area is particularly great as there are no universally-accepted paper-based standards to reference.

Research in which extensive studies of medication-related errors were reviewed, suggests that the most powerful means of preventing medication-related errors are computerised order entry and administration management along with standards for processes and for the writing of prescriptions (see Medication Errors {R4}, To Err Is Human {R5} and Understanding Patient Safety {R6} ).

In the UK, emerging standards and guidelines designed to improve medicines management in the NHS draw attention to the need for active review of long term medications in a Primary Care environment (see Room for Review {R7} and National Service Framework for Older People (NHS) [2] ) . For in-patient settings however, medication reviews are carried out as part of regular and often daily reviews of treatment. Medications are reviewed to assess whether they are achieving the desired therapeutic intent, ensure that there are no more medications prescribed than is necessary and to monitor for adverse effects.

An in-patient review of medications may form only part of a more comprehensive review that depends on other information such as observations, test results and clinical notes (including diagnoses and plans). The information required for a medication review will vary for different

1 NPSA – Safety in doses: medication safety incidents in the NHS {R3} : http://www.npsa.nhs.uk/nrls/alerts-and-directives/directives-guidance/safety-in-doses/

2 National service framework for older people – Department of Health {R8} : http://www.dh.gov.uk/en/publicationsandstatistics/publications/publicationspolicyandguidance/DH_4003066

Page 3

HSCIC Controlled Document

contexts so it is unlikely that the needs for all kinds of medications review would be met by the design of one, specific UI. However, there are needs that are common to all kinds of medications review. Guidance for these areas can help to mitigate errors caused or heightened by inconsistencies of core medications information between systems.

1.2 Scope

This guidance has been designed for the display of medications for a single patient in a hospital ward environment. The guidance applies to the display of information about medications in a list that is organised using columns and rows and specifically to the way that the information is organised and can be manipulated by the clinical user.

1.2.1 In Scope

Users Hospital-based doctors, nurses and pharmacists

Care settings In-patient, hospital ward environment only

Tasks Reviewing medications that have been prescribed for a single patient and checking the accuracy of scripts

Medications  Oral solids and liquids

 Inhalers and sprays

 Eye, ear and nose drops

 Topical liquids

 Creams, ointments and gels

 Enemas and rectal solutions

 Granules and powders

 Insulin

 Suppositories and pessaries

 Topical patches

 Nebuliser solutions

 Simple infusions (by example only)

 Injections (insulin example only)

 Unlicensed medications

Grouping Controls for applying and changing sorting and grouping respectively. The display of group headers, expanding and collapsing groups and handling medications that belong in more than one group

Notifications General notifications, such as ‘Patient nil by mouth’ and recent past medications

Look-ahead scroll bars Generic guidance for the display of a look-ahead scroll bar in any view and guidance that is specific to the display of current medications and past medications. See section 3.3.20 for a description of the lookahead scroll bar.

List structure Structure and layout of a list of medications

Filtering Filtering to display current or past medications respectively and filters to display subsets of past medications

Table 2: In Scope

1.2.2 Out of Scope

Table 3 defines areas that are not covered in this guidance. Although there may be specific risks associated with these areas that are not addressed in this guidance, it is likely that the principles in this guidance will extend to the display of medication information in many of the areas listed below.

The patient is indicated as out of scope in so far as not being a user of clinical software; the guidance is designed to support user interfaces used by clinicians. As such, it will therefore present information in formats that are designed to support health care professionals. The display of medication information in views that are designed for patients is not addressed in this guidance.

The care settings listed in Table 3 are out of scope because they have not been studied in depth in our research. The Medication List guidance is likely to be relevant to all of these care settings, but

Page 4

HSCIC Controlled Document

there may be specific risks associated with each that have not been considered and therefore mitigated in this guidance.

Guidance Areas Details

Users Non-clinical staff, patients and other health care professionals not listed in the in scope section (that is, only hospital-based doctors, nurses and pharmacists are in scope).

Care settings Care settings other than in-patient, hospital ward environments, including: outpatients, clinics, pharmacies, emergency services and departments, intensive care, High Dependency Unit (HDU), primary care, including general practice, community and home visits, ward management, multi-patient tasks.

Tasks  Reviewing administration events to gain an understanding of the degree to which the medication has

been successfully administered

 Relating medications to information elsewhere in the patient record, including the linking of information

in a plan or notes to medications

 Medications reconciliation

Medications

Although these medications can be displayed in the list view defined by this guidance, they may have additional requirements or introduce specific risks that are not explicitly addressed by the guidance.

 Enteral feeds

 Dressings and devices

 Implants and sticks

 Intrauterine devices (IUDs)

 Cements

 Homeopathic products (including

complementary and alternative therapies)

 Dialysis solutions

 Injections (except by specific example)

 Infusions and fluids (except by specific

examples)

 Combination infusions

 Total Parental Nutrition (TPN)

 Gases

 Blood and platelet products

 Radio-pharmacy

 Variable dose medications

 Foams

 Radioactive agents

 Regimens and order sets

 Advisory Committee on Borderline Substances

(ACBS) products

 Over the counter (OTC) medications

 Recreational drugs

 Medications with titrating doses

 Discharge medications – to take out (TTO)

 Patient’s own drugs (PODs)

 Epidurals and patient controlled analgesia

 Extemporaneous prescriptions

 Medication administered or supplied as part of a

Patient Group Direction (PGD)

 Medication prescribed by supplementary

prescribers

Identity of a medication Definition of which attributes can be changed without the need for a new medication line to be represented (in the UI).

All details for one medication

Specific Properties of Individual Medications

Decision and knowledge support

The layout and structure for the presentation of all information about one medication from the selection of a medication anywhere in a clinical application. This includes the selection of a medication to present a separate window or area with more detailed information about that medication.

Guidance for the indication (as text or as an icon) of specific attributes of a medication, including:

 Indicating medications that were added when they were already ‘past’ medications in order to

complete missing information in a past medical history

 Indicating an owner for each medication (for within multi-disciplinary cross boundary records)

All forms of decision support, including alerting for allergies and drug-to-drug interactions. Knowledge support such as browsing drugs by classification and looking up information about medications.

Allergies The display and recording of allergy information and adverse drug reaction risks is covered in a separate guidance document.

Patient consent and preference

Patient preference, such as for a particular drug form. Patient consent, particularly in a mental health context.

Page 5

HSCIC Controlled Document

Guidance Areas Details

Other  Sealed envelopes

 Supply and dispensing

 Guidance (other than notifications) that might be needed for when a patient is ‘Nil by Mouth’

Table 3: Out of Scope

1.3 Dependencies

D1 This guidance is informed by ongoing and unpublished work by the NHS National Programme for IT (NPfIT) that is referred to in this document as NHS Connecting for Health (NHS CFH) Medication Types Rules. The NHS CFH Medication Types Rules is still evolving and is based on extensive research and consultation. Changes to this work may trigger changes to this guidance.

D2 This guidance is informed by the NHS NPfIT ePrescribing Functional Specification [3]

D3 This guidance uses the concepts ‘generic drug’ and ‘brand name’ and depends on access to, or creation of, a database or dictionary, that can support these concepts, such as the Dictionary of Medicines and Devices (known as ‘dm+d’) [4].

D4 This guidance includes guidance points for filtering, sorting and grouping that are expected to be included in a separate guidance document for this area. Availability of such a document may trigger changes to this guidance.

D5 This guidance assumes that a list of medications is provided as part of a larger framework of medications that collectively provide enough information to support a review of the current and past medications of a single patient. A comprehensive understanding of the current status of a patient’s medications is expected to be gained from the use of more than one medications view.

Table 4: Dependencies

3 NHS NPfIT – ePrescribing Functional Specification {R9} : http://www.connectingforhealth.nhs.uk/newsroom/news-stories/eprescfunctspec

4 Dictionary of Medicines and Devices {R10} : http://www.dmd.nhs.uk/

Page 6

HSCIC Controlled Document

2 GUIDANCE OVERVIEW

Important

The visual representations used within this document to display the guidance are illustrative only. They are simplified in order to support understanding of the guidance points in each section respectively, so some details that are included in usage examples are excluded from the summary. Stylistic choices such as colours, fonts or icons, are not part of the guidance and, unless otherwise specified, are therefore not mandatory requirements for compliance with the guidance in this document.

2.1 Summary of Guidance

Detailed guidance and rationale for all guidance points is in sections 3.3.1 to 3.3.38. Refer to APPENDIX A for a reference list of all the guidance descriptions. Table 5 provides a summary of the guidance.

Note

In the Visual Summary column, items highlighted in blue indicate correct usage and those in red indicate incorrect usage.

MEDv-020 MEDv-141

3.3.1 Tabular Layout

Col1	sentence	tabula

xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz
xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz
xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz
xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz

MEDv-142 3.3.2 Indicating List Length

MEDv-021 3.3.3 Gridlines

xxxx – xxxx - xxxx yyyy zzzz xxxx – xxxx - xxxx yyyy zzzz xxxx – xxxx - xxxx yyyy zzzz xxxx – xxxx - xxxx yyyy zzzz	Col2

	space

Col1	no strong

xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz
xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz
xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz
xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz

MEDv-022 MEDv-143 to MEDv-145

3.3.4 Row Formatting

Alternate row shading and lines between rows.

MEDv-023 3.3.5 Displaying Icons for Drug Details

Col1	Col2	icons	Col4

xxxx– xxxx - xx	A	B	yyyy zzzz
xxxx– xxxx - xx yyyy zzzz B	xxxx– xxxx - xx yyyy zzzz B	xxxx– xxxx - xx yyyy zzzz B	xxxx– xxxx - xx yyyy zzzz B
xxxx– xxxx - xx	A	yyyy zzzz	yyyy zzzz

Page 7

HSCIC Controlled Document

MEDv-146 3.3.6 Empty Lists

aaaa	bbbb	cccc
There are no current medications for this patient empty list message	There are no current medications for this patient empty list message	There are no current medications for this patient empty list message

MEDv-147 to MEDv-150

MEDv-151 to MEDv-154

MEDv-155 to MEDv-157

MEDv-027 MEDv-158

MEDv-159 to MEDv-161

MEDv-162 to MEDv-165

MEDv-166 to MEDv-173

MEDv-024 MEDv-025 MEDv-042

MEDv-062 to MEDv-067 MEDv-174

3.3.7 Mandatory Columns

3.3.8 Date Columns

Relative placement of date columns, column widths and recommended date columns to include.

3.3.9 Column Headings

How to label columns appropriately.

3.3.10 Composite Columns

How to combine information into a single column.

3.3.11 Constraining Dimensions

How to ensure appropriate column and overall list widths.

3.3.12 Displaying Status

How to display status for medications in the list.

3.3.13 Specific Status Values

Recommended values to use for status.

3.3.14 Formatting Status

How to format the display of status.

3.3.15 Controls for Displaying Current and Past Medications

Drug Details	Status	Date

mandatory columns

Col1	Col2	Col3
Start	Start	End

First Administration

Last Administration

Start and End Dates Start zzzz

End zzzz

Start zzzz

End zzzz

aaaa	bbbb	cccc
relative widths

Current Past

Status Started

Not Started

Suspended

Current

Past

Status Completed

Discontinued

Started

Not Started

Suspended

Completed

Discontinued

xxxx – xxxx - xxxx yyyy zzzz	Col2
xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz
xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz
xxxx– xxxx - xxxx	yyyy zzzz
	Important S

Page 8

HSCIC Controlled Document

MEDv-099 MEDv-173

MEDv-074 MEDv-075 MEDv-077 MEDv-174

MEDv-100 MEDv-175

MEDv-068 to MEDv-073

MEDv-176

MEDv-177 to MEDv-181

MEDv-058 MEDv-059 MEDv-182

MEDv-043 to MEDv-045

3.3.16 Displaying Current Medications

3.3.17 Displaying Recent Past Notifications

How to present a notification for recently past medications.

3.3.18 Displaying Past Medications

Sort order and column placement for past medications.

3.3.19 Filtering Past Medications

How to support filtering for past medications.

3.3.20 Displaying a LASB

How to present a look-ahead scroll bar.

3.3.21 Defining LASB Interactions

How a look-ahead scroll bar should behave.

3.3.22 Displaying LASB Notifications

How to present look-ahead scroll bar notifications

Drug Details	xxxx	Start ▼
	default sort	default sort

Status	Col2	Drug Details	End ▼
		default sort	default sort
	first column	first column	first column

Col2	Col3	Col4	Col5




reserved space	reserved space	reserved space	reserved space

Col1	Col2	Col3
ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx yyyy zzzz yyyy zzzz yyyy zzzz	ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx yyyy zzzz yyyy zzzz yyyy zzzz	ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx yyyy zzzz yyyy zzzz yyyy zzzz

Current

first column

Current

Past

joined to scroll bar	Col2	Col3




single line	single line	single line

Page 9

HSCIC Controlled Document

MEDv-049 MEDv-183

MEDv-048 MEDv-052 MEDv-053 MEDv-055

MEDv-056 MEDv-184 MEDv-185

MEDv-050 MEDv-051

MEDv-186 to MEDv-189

3.3.23 Selecting LASB Contents

How to determine what the contents of a look-ahead scroll bar notification should be

3.3.24 Displaying LASB Contents

How to display the contents of a look-ahead scroll bar notification

3.3.25 Formatting LASB Contents

How to format the contents of a look-ahead scroll bar notification.

3.3.26 Drug Names in the LASB

How to present drug names in the look-ahead scroll bar notification.

3.3.27 Formatting LASB Notifications

How to format the look-ahead scroll bar notifications.

aaa – xxxx - xxxx	l
bbb– xxxx - xxxx	bbb– xxxx - xxxx
ccc– xxxx - xxxx	ccc– xxxx - xxxx
ccc– xxxx - xxxx	l
ddd– xxxx - xxxx	ddd– xxxx - xxxx
eee– xxxx - xxxx	eee– xxxx - xxxx
fff– xxxx - xxxx	fff– xxxx - xxxx

Col1	Col2	aaa ·	bbb
ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx yyyy zzzz yyyy zzzz yyyy zzzz	ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx yyyy zzzz yyyy zzzz yyyy zzzz	ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx yyyy zzzz yyyy zzzz yyyy zzzz	ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx yyyy zzzz yyyy zzzz yyyy zzzz
	2 more· kkk· jjj· iii· ggg· fff	2 more· kkk· jjj· iii· ggg· fff	2 more· kkk· jjj· iii· ggg· fff

Col1	text	Col3

atenolol· fluoxetine· naproxen	atenolol· fluoxetine· naproxen	atenolol· fluoxetine· naproxen
		background

Past Current

visible list

MEDv-054 3.3.28 Displaying a LASB for Past Medications

How to display a look-ahead scroll bar in past medications.

Col1	2 more
ppp– xxxx - xxxx qqq– xxxx - xxxx ooo– xxxx - xxxx	ppp– xxxx - xxxx qqq– xxxx - xxxx ooo– xxxx - xxxx
	4 more

Col1	Col2	aaa · bbb
ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx	ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx	ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx
	2 more · ggg· fff	2 more · ggg· fff

MEDv-084 MEDv-085 MEDv-190

MEDv-083 MEDv-087 MEDv-191 to MEDv-193

MEDv-086 MEDv-090 MEDv-091 MEDv-194 MEDv-195

3.3.29 Providing a Grouping Control

How to provide a control to support grouping and the display of the currently selected group.

3.3.30 Supporting Grouping

How to support grouping within the list.

3.3.31 Displaying Group Headings

How to display headings for groups.

Group A

xxxx - xxxx - xxxx

Group B

yyyy zzzz

xxxx - xxxx - xxxx yyyy zzzz

xxxx - xxxx - xxxx

yyyy zzzz

Tablet	Col2
xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz
(No Form Specified)	(No Form Specified)
xxxx– xxxx - xxxx yyyy zzzz xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz xxxx– xxxx - xxxx yyyy zzzz

Page 10

HSCIC Controlled Document

MEDv-089 MEDv-092 MEDv-093 MEDv-196

MEDv-197 to MEDv-200

MEDv-101 to MEDv-105

3.3.32 Collapsing Groups

How to support expanding and collapsing of groups.

3.3.33 Combining Groups to Avoid Duplication

How to combine groups for medications that belong to more than one group.

3.3.34 Supporting Sorting

How to support changing the sort order.

Col1	Col2	Col3	Col4
aaaa	Start▼	Start▼	Start▼
aaaa	Start▼
zzzz yyyy xxxx aaaa aaaa aaaa	zzzz yyyy xxxx aaaa aaaa aaaa

MEDv-201 3.3.35 Supporting Levels of Detail

How to support access to medication lists that display different details.

xxxx – xxxx - xxxx yyyy	Col2
xxxx– xxxx - xxxx yyyy	xxxx– xxxx - xxxx yyyy
xxxx– xxxx - xxxx yyyy
xxxx– xxxx - xxxx yyyy	xxxx– xxxx - xxxx yyyy

formatting

MEDv-122 to MEDv-127 MEDv-202 MEDv-203

MEDv-128 to MEDv-133

MEDv-135 MEDv-136

3.3.36 Supporting Selection and Action

How to support selection of list items and access relevant actions.

3.3.37 Providing Context Menus

How to present a context menu.

3.3.38 Providing Access to Medication Details

How to support access to detailed information about a selected medication.

xxxx – xxxx - xxxx yyyy zzzz	Col2	Col3
xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz
xxxx– xxxx - xxxx yyyy zzzz ~~Action 1~~	xxxx– xxxx - xxxx yyyy zzzz ~~Action 1~~	xxxx– xxxx - xxxx yyyy zzzz ~~Action 1~~
xxxx– xxxx - xxxx yyyy zzzz ~~Action 1~~	yyyy zzzz ~~Action 1~~	yyyy zzzz ~~Action 1~~
xxxx– xxxx - xxxx	yyyy zzzz Action 2
	Action 3

xxxx – xxxx - xxxx yyyy zzzz	Col2	Col3
xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz
xxxx–	xxxx - xxxx yyyy zzzz	xxxx - xxxx yyyy zzzz
xxxx–	xxxx - xxxx yyyy zzzz	xxxx - xxxx yyyy zzzz
xxxx–	xxxx - xxxx yyyy zzzz ~~Detailed informat~~	xxxx - xxxx yyyy zzzz ~~Detailed informat~~

Table 5: Summary of Guidance

Page 11

HSCIC Controlled Document

3 GUIDANCE DETAILS

3.1 Introduction

This section contains detailed guidance for the display of a list of medications that have been prescribed for a single patient. A list of medications is expected to be one of many ways of displaying medications information for a single patient. This list of medications forms only part of the medications management views and tools that would be available in a clinical application.

A full framework for medications management in a clinical application might include:

The definition of a set of views each of which has a different focus and presentation style
The definition of specialist views that combine information in a particular way for use in

specific contexts. For example, a monitoring chart for tracking medication doses, observations and test results in a high dependency unit, or a Timeline View for long term management of diabetes

Mechanisms for accessing medications management tools and navigating between

medications views. These may be dependent on the application architecture

The degree to which, and means by which, medications information is integrated into other

parts of a clinical application

The dimensions of each of the medications views and the way in which they integrate into

the surrounding application. This includes whether views are panels, separate windows or full-screen views and defines how the user navigates between and interacts with them. Figure 1 shows an example of a full width medications view and Figure 2 shows a medications view displayed alongside another view.

Global Navigation

Patient Banner

Col1	Col2

	Medications View

Figure 1: A Medications View Within a Clinical Application

Patient Banner

Global Navigation

Medications Toolbar

Col1	Col2	Other Toolbar Other View

Medications View

Figure 2: A Medications View Displayed Alongside Another View

Page 12

HSCIC Controlled Document

The CUI program provides design guidance for selected medications views that are expected to be commonly used and that would provide more benefit to the user by being consistent between clinical applications.

A common set of medications views is expected to include:

A Medications List View, in line with the guidance in this document
A Drug Administration View, in line with the guidance in Drug Administration {R11}
A Timeline View, in which medications and associated events are plotted along a vertical

timescale. A Timeline View could be designed to support users reviewing sequences of medications-related events and allow users to review medications being taken on a specific day or within a date range

A view in which medication doses can be tracked alongside related test results and

recorded observations

Medications information is not only displayed in views that are dedicated to medications management. The Medication Line {R2} design guidance defines display rules that remain consistent wherever a medication is displayed. Figure 3 shows medications information displayed in a view that focuses on other (non-medications) information:

Patient Banner Global Navigation Other Toolbar	Col2	Col3	Medications information displayed within a view that is designed to display other information
Patient Banner Global Navigation Other Toolbar		Other View	Other View
Other Toolbar	Other Toolbar	Other Toolbar	Other Toolbar

Figure 3: Medications Information Displayed as Part of a View that is Designed to Display Other Information

Although not displayed within a Medications List View, Drug Administration View or Timeline View, the medications information must still conform to the Medication Line {R2} design guidance.

3.2 Principles

The following key principles inform the guidance in this section:

Provide the information required to make a high-level clinical assessment of the patient’s

medications

Restrict the display of unnecessary information to reduce clutter and prioritise information

most likely to require action

Provide access in context to further details on demand
Mitigate the potential for action to be taken without sufficient information by presenting

carefully selected information by default, avoiding occlusion and providing clear signposts to further information.

Describe inclusion criteria clearly by providing explicit labels to clarify what information is

displayed and the extent to which it is complete

Page 13

HSCIC Controlled Document

3.3 Guidelines

Figure 4 is a simplified diagram that shows how some of the areas of guidance fit together in a Medications List View:

Current and Past Menu Buttons

Grouping Control

bar notification

Drug Details	yyyy	zzzz	Start ▼	Col5
Drug Details	yyyy	aaa·	aaa·	bbb

Medications

Group Headings

Notification

Look-ahead scroll bar notification

Figure 4: Key Parts of a Medications List View

Page 14

HSCIC Controlled Document

3.3.1 Tabular Layout

Page 15

temazepam – tablet – DOSE 20 mg – oral – at night Started 26-May-2010	oxygen 60% – inhalation gas – RATE 15 L per minute – continuous – with non re-breather bag Started 25-May-2010
co-amilofruse– 5 mgand40 mg in 5 mL – solution –`DOSE` 5 mL– oral – once a day Started24-May-2010	salbutamol– 100 micrograms per dose – metered dose inhaler – `DOSE` 2 puffs– inhaled – four times a day as required Started24-May-2010

HSCIC Controlled Document

Page 16

HSCIC Controlled Document

3.3.2 Indicating List Length

For the sake of brevity, the usage examples in this section omit look-ahead scroll bar notifications. Refer to sections 3.3.21 to 3.3.28 for guidance on the look-ahead scroll bar and to sections 3.3.20 and 3.3.22 for specific guidance on reserving space for and displaying the look-ahead scroll bar notifications.

Page 17

HSCIC Controlled Document

3.3.3 Gridlines

temazepam – tablet – DOSE 20 mg – oral – at night	Started	26-May-2010
oxygen 60% – inhalation gas –`RATE` 15 L per minute– continuous – with non re-breather bag	Started	25-May-2010
co-amilofruse– 5 mgand40 mg in 5 mL – solution – `DOSE` 5 mL– oral – once a day	Started	24-May-2010
salbutamol– 100 micrograms per dose – metered dose inhaler –`DOSE` 2 puffs– inhaled – four times a day as required	Started	24-May-2010

temazepam – tablet – DOSE 20 mg – oral – at night	Started	26-May-2010
salbutamol– 100 micrograms per dose – metered dose inhaler –`DOSE` 2 puffs– inhaled – four times a day as required	Started	24-May-2010
co-amilofruse– 5 mgand40 mg in 5 mL – solution – `DOSE` 5 mL– oral – once a day	Started	24-May-2010

Page 18

HSCIC Controlled Document

3.3.4 Row Formatting

5 Web Content Accessibility Guidelines 1.0 {R13} : http://www.w3.org/TR/WAI-WEBCONTENT/

6 Techniques for Accessibility Evaluation and Repair Tools – Technique 2.2.1 {R14} : http://www.w3.org/TR/AERT#color-contrast

Page 19

HSCIC Controlled Document

3.3.5 Displaying Icons for Drug Details

3.3.6 Empty Lists

Drug Details	Status
There are no current medications for this patient	There are no current medications for this patient

Page 20

HSCIC Controlled Document

3.3.7 Mandatory Columns

Col1	Col2	Col3	Col4
Drug Details	Drug Details	Status	Start Date ▼
	6 more· metformin· glicazide· glyceryl trinitrate· dalteparin· aspirin· isosorbide mononitrate	6 more· metformin· glicazide· glyceryl trinitrate· dalteparin· aspirin· isosorbide mononitrate	6 more· metformin· glicazide· glyceryl trinitrate· dalteparin· aspirin· isosorbide mononitrate
25-May-2010 26-May-2010 Started Started oxygen 60% – inhalation gas –`RATE` 15 L per minute– continuous – with non re-breather bag temazepam– tablet –`DOSE` 20 mg– oral – at night co-amilofruse– 5 mgand40 mg in 5 mL – solution – 24-May-2010 Started	25-May-2010 26-May-2010 Started Started oxygen 60% – inhalation gas –`RATE` 15 L per minute– continuous – with non re-breather bag temazepam– tablet –`DOSE` 20 mg– oral – at night co-amilofruse– 5 mgand40 mg in 5 mL – solution – 24-May-2010 Started	25-May-2010 26-May-2010 Started Started oxygen 60% – inhalation gas –`RATE` 15 L per minute– continuous – with non re-breather bag temazepam– tablet –`DOSE` 20 mg– oral – at night co-amilofruse– 5 mgand40 mg in 5 mL – solution – 24-May-2010 Started	25-May-2010 26-May-2010 Started Started oxygen 60% – inhalation gas –`RATE` 15 L per minute– continuous – with non re-breather bag temazepam– tablet –`DOSE` 20 mg– oral – at night co-amilofruse– 5 mgand40 mg in 5 mL – solution – 24-May-2010 Started
`DOSE` 5 mL– oral – once a day	`DOSE` 5 mL– oral – once a day	`DOSE` 5 mL– oral – once a day	`DOSE` 5 mL– oral – once a day

Page 21

HSCIC Controlled Document

3.3.8 Date Columns

The guidance in this section refers to date columns. The specific information to display in these columns is not part of guidance because needs differ between tasks and contexts. Guidance is provided for the relative placement of date columns when there are columns such as ‘Date Prescribed’ or ‘First Administration’ that include date and time information.

In what follows, columns that contain date and time information for the start or initiation of a medication are referred to as ‘start date’. Columns that contain date and time information for an end or completion of a medication are referred to as ‘end date’. The guidance does not refer to the relative placement of any other date columns (such as ‘Review Date’) that may be present.

Page 22

Col1	Status	End Date	Date Prescribed ▼
03-Jun-2010 Started 26-May-2010	03-Jun-2010 Started 26-May-2010	03-Jun-2010 Started 26-May-2010	03-Jun-2010 Started 26-May-2010
09-Jun-2010 Started 25-May-2010	09-Jun-2010 Started 25-May-2010	09-Jun-2010 Started 25-May-2010	09-Jun-2010 Started 25-May-2010
06-Jun-2010 Started 24-May-2010	06-Jun-2010 Started 24-May-2010	06-Jun-2010 Started 24-May-2010	06-Jun-2010 Started 24-May-2010

Col1	Status	Start Date	End Date ▼
26-May-2010 Started 03-Jun-2010	26-May-2010 Started 03-Jun-2010	26-May-2010 Started 03-Jun-2010	26-May-2010 Started 03-Jun-2010
25-May-2010 Started 08-Jun-2010	25-May-2010 Started 08-Jun-2010	25-May-2010 Started 08-Jun-2010	25-May-2010 Started 08-Jun-2010
24-May-2010 Started 07-Jun-2010	24-May-2010 Started 07-Jun-2010	24-May-2010 Started 07-Jun-2010	24-May-2010 Started 07-Jun-2010

Col1	Status	First Administration ▼	End Date

03-Jun-2010 Started 26-May-2010	03-Jun-2010 Started 26-May-2010	03-Jun-2010 Started 26-May-2010	03-Jun-2010 Started 26-May-2010
09-Jun-2010 Started 25-May-2010	09-Jun-2010 Started 25-May-2010	09-Jun-2010 Started 25-May-2010	09-Jun-2010 Started 25-May-2010
06-Jun-2010 Started 24-May-2010	06-Jun-2010 Started 24-May-2010	06-Jun-2010 Started 24-May-2010	06-Jun-2010 Started 24-May-2010

HSCIC Controlled Document

Page 23

HSCIC Controlled Document

3.3.9 Column Headings

Page 24

HSCIC Controlled Document

3.3.10 Composite Columns

Status Review and End Dates ▼ Started 06-Jun-2010 End 12-Jun-2010	Status	Review and End Dates ▼
08-Jun-2010 End08-Jun-2010 Started	08-Jun-2010 End08-Jun-2010 Started	08-Jun-2010 End08-Jun-2010 Started

Page 25

HSCIC Controlled Document

3.3.11 Constraining Dimensions

Col1	Col2	Col3	Col4
Drug Details	Drug Details	Status	Start Date ▼
	6 more· metformin· glicazide· glyceryl trinitrate· dalteparin· aspirin· isosorbide mononitrate	6 more· metformin· glicazide· glyceryl trinitrate· dalteparin· aspirin· isosorbide mononitrate	6 more· metformin· glicazide· glyceryl trinitrate· dalteparin· aspirin· isosorbide mononitrate
25-May-2010 26-May-2010 Started Started oxygen 60% – inhalation gas –`RATE` 15 L per minute– continuous – with non re-breather bag temazepam– tablet –`DOSE` 20 mg– oral – at night co-amilofruse– 5 mgand40 mg in 5 mL – solution – 24-May-2010 Started	25-May-2010 26-May-2010 Started Started oxygen 60% – inhalation gas –`RATE` 15 L per minute– continuous – with non re-breather bag temazepam– tablet –`DOSE` 20 mg– oral – at night co-amilofruse– 5 mgand40 mg in 5 mL – solution – 24-May-2010 Started	25-May-2010 26-May-2010 Started Started oxygen 60% – inhalation gas –`RATE` 15 L per minute– continuous – with non re-breather bag temazepam– tablet –`DOSE` 20 mg– oral – at night co-amilofruse– 5 mgand40 mg in 5 mL – solution – 24-May-2010 Started	25-May-2010 26-May-2010 Started Started oxygen 60% – inhalation gas –`RATE` 15 L per minute– continuous – with non re-breather bag temazepam– tablet –`DOSE` 20 mg– oral – at night co-amilofruse– 5 mgand40 mg in 5 mL – solution – 24-May-2010 Started
`DOSE` 5 mL– oral – once a day	`DOSE` 5 mL– oral – once a day	`DOSE` 5 mL– oral – once a day	`DOSE` 5 mL– oral – once a day

Drug Details	Status	First Admin
glyceryl trinitrate – 400 micrograms per dose – sublingual spray – `DOSE` 1 to 2 puffs– sublingual – as required – maximum 3 doses in 15 minutes Suspendedon 30-May-2008 26-May-20	glyceryl trinitrate – 400 micrograms per dose – sublingual spray – `DOSE` 1 to 2 puffs– sublingual – as required – maximum 3 doses in 15 minutes Suspendedon 30-May-2008 26-May-20	glyceryl trinitrate – 400 micrograms per dose – sublingual spray – `DOSE` 1 to 2 puffs– sublingual – as required – maximum 3 doses in 15 minutes Suspendedon 30-May-2008 26-May-20
lansoprazole – orodispersible tablet – `DOSE` 30 mg– oral – once a day Started 25-May-20	lansoprazole – orodispersible tablet – `DOSE` 30 mg– oral – once a day Started 25-May-20	lansoprazole – orodispersible tablet – `DOSE` 30 mg– oral – once a day Started 25-May-20

Page 26

Drug Details	Status	First Admin
glyceryl trinitrate – 400 micrograms per dose – sublingual spray –`DOSE` 1 to 2 puffs– sublingual – as required – maximum 3 doses in 15 minutes Suspendedon 30-May-2008 26-May-20	glyceryl trinitrate – 400 micrograms per dose – sublingual spray –`DOSE` 1 to 2 puffs– sublingual – as required – maximum 3 doses in 15 minutes Suspendedon 30-May-2008 26-May-20	glyceryl trinitrate – 400 micrograms per dose – sublingual spray –`DOSE` 1 to 2 puffs– sublingual – as required – maximum 3 doses in 15 minutes Suspendedon 30-May-2008 26-May-20
lansoprazole – orodispersible tablet – `DOSE` 30 mg– oral – once a day Started 25-May-20	lansoprazole – orodispersible tablet – `DOSE` 30 mg– oral – once a day Started 25-May-20	lansoprazole – orodispersible tablet – `DOSE` 30 mg– oral – once a day Started 25-May-20
dalteparin – 10,000 units per 1 mL – injection – `DOSE` 10,000 units– subcutaneous – twice a day Started 24-May-20	dalteparin – 10,000 units per 1 mL – injection – `DOSE` 10,000 units– subcutaneous – twice a day Started 24-May-20	dalteparin – 10,000 units per 1 mL – injection – `DOSE` 10,000 units– subcutaneous – twice a day Started 24-May-20

HSCIC Controlled Document

Page 27

HSCIC Controlled Document

3.3.12 Displaying Status

Page 28

Status First Administration ▼ Not Started 29-May-2010 Verified	Status	First Administration ▼
27-May-2010 Started Not Verified	27-May-2010 Started Not Verified	27-May-2010 Started Not Verified
25-May-2010 Started Verified	25-May-2010 Started Verified	25-May-2010 Started Verified

Status First Administration ▼ Not Started 29-May-2010 Verified	Status	First Administration ▼
27-May-2010 Not Verified	27-May-2010 Not Verified	27-May-2010 Not Verified
25-May-2010 Started Verified	25-May-2010 Started Verified	25-May-2010 Started Verified

Status First Administration ▼ 29-May-2010	Status	First Administration ▼
27-May-2010 Started Not Verified	27-May-2010 Started Not Verified	27-May-2010 Started Not Verified
25-May-2010 Started Verified	25-May-2010 Started Verified	25-May-2010 Started Verified

HSCIC Controlled Document

Page 29

HSCIC Controlled Document

3.3.13 Specific Status Values

Page 30

HSCIC Controlled Document

Design Analysis:

This guidance aims to introduce a set of status values that::

 Are more detailed than simply ‘current’ and ‘past’

 Are relevant to all care settings and can be supplemented to add granularity

 Can be used in conjunction with other, more granular sets of status values.

Page 31

HSCIC Controlled Document

3.3.14 Formatting Status

Page 32

Status First Administration ▼ Not Started 29-May-2010	Status	First Administration ▼
27-May-2010 Started	27-May-2010 Started	27-May-2010 Started
25-May-2010 Started	25-May-2010 Started	25-May-2010 Started

Status	Drug Details

hydrochloro Completed	hydrochloro Completed
methyldopa – Discontinued	methyldopa – Discontinued
furosemide – Completed	furosemide – Completed

HSCIC Controlled Document

Status First Administration ▼ Not Started 29-May-2010	Status	First Administration ▼
27-May-2010 Started	27-May-2010 Started	27-May-2010 Started
25-May-2010 Started	25-May-2010 Started	25-May-2010 Started

Page 33

HSCIC Controlled Document

3.3.15 Controls for Displaying Current and Past Medications

Page 34

HSCIC Controlled Document

Page 35

HSCIC Controlled Document

3.3.16 Displaying Current Medications

Page 36

Status First Administration ▼ Not Started 29-May-2010	Status	First Administration ▼
27-May-2010 Started	27-May-2010 Started	27-May-2010 Started
25-May-2010 Started	25-May-2010 Started	25-May-2010 Started

Status First Administration ▲ Started 25-May-2010	Status	First Administration ▲
27-May-2010 Started	27-May-2010 Started	27-May-2010 Started
29-May-2010 Not Started	29-May-2010 Not Started	29-May-2010 Not Started

Drug Details	Status
glyceryl trinitrate – 400 micrograms per dose – sublingual spray –`DOSE` 1 to 2 puffs– sublingual – as required – maximum 3 doses in 15 minutes Suspen 30-May	glyceryl trinitrate – 400 micrograms per dose – sublingual spray –`DOSE` 1 to 2 puffs– sublingual – as required – maximum 3 doses in 15 minutes Suspen 30-May
lansoprazole – orodispersible tablet – `DOSE` 30 mg– oral – once a day Started	lansoprazole – orodispersible tablet – `DOSE` 30 mg– oral – once a day Started
dalteparin – 10,000 units per 1 mL – injection – `DOSE` 10,000 units– subcutaneous – twice a day Started	dalteparin – 10,000 units per 1 mL – injection – `DOSE` 10,000 units– subcutaneous – twice a day Started

Status	Drug Details
Started Not Started Started glyceryl trinitrate sublingual spray as required – max lansoprazole – `DOSE` 30 mg– dalteparin – `DOSE` 10,000	Started Not Started Started glyceryl trinitrate sublingual spray as required – max lansoprazole – `DOSE` 30 mg– dalteparin – `DOSE` 10,000

HSCIC Controlled Document

Page 37

HSCIC Controlled Document

3.3.17 Displaying Recent Past Notifications

Page 38

HSCIC Controlled Document

Page 39

HSCIC Controlled Document

3.3.18 Displaying Past Medications

Page 40

Drug Details	Last Administration ▼

26-May-2010 `E` 100 mg – oral – 4 times a day	26-May-2010 `E` 100 mg – oral – 4 times a day
g – oral – twice a day 25-May-2010	g – oral – twice a day 25-May-2010
24-May-2010 – oral – once a day	24-May-2010 – oral – once a day

Drug Details	Last Administration ▲

24-May-2010 – oral – once a day	24-May-2010 – oral – once a day
g – oral – twice a day 25-May-2010	g – oral – twice a day 25-May-2010
26-May-2010 `E` 100 mg – oral – 4 times a day	26-May-2010 `E` 100 mg – oral – 4 times a day

Status	Drug Details
hydrochlorothiazide – tablet –`DOSE` 100 mg – ora Completed	hydrochlorothiazide – tablet –`DOSE` 100 mg – ora Completed
methyldopa – tablet –`DOSE` 250 mg – oral – twice Discontinued	methyldopa – tablet –`DOSE` 250 mg – oral – twice Discontinued
furosemide – tablet –`DOSE` 40 mg – oral – once a Completed	furosemide – tablet –`DOSE` 40 mg – oral – once a Completed

Drug Details	Status	Col3

hydrochlorothiazide – tablet –`DOSE` 100 mg – oral – 4 times a day Completed	hydrochlorothiazide – tablet –`DOSE` 100 mg – oral – 4 times a day Completed	hydrochlorothiazide – tablet –`DOSE` 100 mg – oral – 4 times a day Completed
methyldopa – tablet –`DOSE` 250 mg – oral – twice a day Discontinue	methyldopa – tablet –`DOSE` 250 mg – oral – twice a day Discontinue	methyldopa – tablet –`DOSE` 250 mg – oral – twice a day Discontinue
furosemide – tablet –`DOSE` 40 mg – oral – once a day Completed	furosemide – tablet –`DOSE` 40 mg – oral – once a day Completed	furosemide – tablet –`DOSE` 40 mg – oral – once a day Completed

HSCIC Controlled Document

Page 41

HSCIC Controlled Document

3.3.19 Filtering Past Medications

Page 42

Status	Drug Details	Col3
This list is filtered to show: Past 2 months Remove Filter	This list is filtered to show: Past 2 months Remove Filter	This list is filtered to show: Past 2 months Remove Filter
		aspirin· isosorbide
hydrochlorothiazide – tablet –`DOSE` 100 mg – ora Completed	hydrochlorothiazide – tablet –`DOSE` 100 mg – ora Completed	hydrochlorothiazide – tablet –`DOSE` 100 mg – ora Completed
methyldopa – tablet –`DOSE` 250 mg – oral – twice Discontinued	methyldopa – tablet –`DOSE` 250 mg – oral – twice Discontinued	methyldopa – tablet –`DOSE` 250 mg – oral – twice Discontinued
furosemide – tablet –`DOSE` 40 mg – oral – once a Completed	furosemide – tablet –`DOSE` 40 mg – oral – once a Completed	furosemide – tablet –`DOSE` 40 mg – oral – once a Completed

This list is filtered to show: Past 2 months Remove Filter	Col2	Col3
Status	Drug Details	Drug Details
		aspirin· isosorbide
hydrochlorothiazide – tablet –`DOSE` 100 mg – ora Completed	hydrochlorothiazide – tablet –`DOSE` 100 mg – ora Completed	hydrochlorothiazide – tablet –`DOSE` 100 mg – ora Completed
methyldopa – tablet –`DOSE` 250 mg – oral – twice Discontinued	methyldopa – tablet –`DOSE` 250 mg – oral – twice Discontinued	methyldopa – tablet –`DOSE` 250 mg – oral – twice Discontinued

Status	Drug Details	Col3
This list is filtered to show: Past 2 months	This list is filtered to show: Past 2 months	This list is filtered to show: Past 2 months
		aspirin· isosorbide
hydrochlorothiazide – tablet –`DOSE` 100 mg – ora Completed	hydrochlorothiazide – tablet –`DOSE` 100 mg – ora Completed	hydrochlorothiazide – tablet –`DOSE` 100 mg – ora Completed
methyldopa – tablet –`DOSE` 250 mg – oral – twice Discontinued	methyldopa – tablet –`DOSE` 250 mg – oral – twice Discontinued	methyldopa – tablet –`DOSE` 250 mg – oral – twice Discontinued

HSCIC Controlled Document

Page 43

HSCIC Controlled Document

3.3.20 Displaying a LASB

Sections 3.3.20 to 3.3.28 include guidance for look-ahead scroll bars. A look-ahead scroll bar is a standard scroll bar that is supplemented with notifications at the top and bottom to indicate that

Look-ahead scroll bar notification

Look-ahead scroll bar

Look-ahead scroll bar notification

Medications

Drug Details	Col2	yyyy	zzzz	Start ▼	Col6
			aaa·	aaa·	bbb
ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx yyyy zzzz yyyy zzzz yyyy zzzz fff– xxxx - xxxx yyyy zzzz ggg– xxxx - xxxx yyyy zzzz hhh– xxxx - xxxx yyyy zzzz iii– xxxx - xxxx yyyy zzzz jjj– xxxx - xxxx yyyy zzzz	ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx yyyy zzzz yyyy zzzz yyyy zzzz fff– xxxx - xxxx yyyy zzzz ggg– xxxx - xxxx yyyy zzzz hhh– xxxx - xxxx yyyy zzzz iii– xxxx - xxxx yyyy zzzz jjj– xxxx - xxxx yyyy zzzz	ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx yyyy zzzz yyyy zzzz yyyy zzzz fff– xxxx - xxxx yyyy zzzz ggg– xxxx - xxxx yyyy zzzz hhh– xxxx - xxxx yyyy zzzz iii– xxxx - xxxx yyyy zzzz jjj– xxxx - xxxx yyyy zzzz	ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx yyyy zzzz yyyy zzzz yyyy zzzz fff– xxxx - xxxx yyyy zzzz ggg– xxxx - xxxx yyyy zzzz hhh– xxxx - xxxx yyyy zzzz iii– xxxx - xxxx yyyy zzzz jjj– xxxx - xxxx yyyy zzzz	ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx yyyy zzzz yyyy zzzz yyyy zzzz fff– xxxx - xxxx yyyy zzzz ggg– xxxx - xxxx yyyy zzzz hhh– xxxx - xxxx yyyy zzzz iii– xxxx - xxxx yyyy zzzz jjj– xxxx - xxxx yyyy zzzz	ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx yyyy zzzz yyyy zzzz yyyy zzzz fff– xxxx - xxxx yyyy zzzz ggg– xxxx - xxxx yyyy zzzz hhh– xxxx - xxxx yyyy zzzz iii– xxxx - xxxx yyyy zzzz jjj– xxxx - xxxx yyyy zzzz
	2 more · ooo· nnn· mmm · lll· kkk	2 more · ooo· nnn· mmm · lll· kkk	2 more · ooo· nnn· mmm · lll· kkk	2 more · ooo· nnn· mmm · lll· kkk	2 more · ooo· nnn· mmm · lll· kkk

Alert icon

Figure 5: Diagram of a Medication List View with Look-ahead Scroll Bars

Page 44

Col1	Col2	Status	Start Date ▼
	aspirin· isosorbide mononitrate	aspirin· isosorbide mononitrate	aspirin· isosorbide mononitrate
25-May-2010 26-May-2010 Started Started `ATE` 15 L per minute– bag 0 mg– oral – at night in 5 mL – solution – 24-May-2010 Started	25-May-2010 26-May-2010 Started Started `ATE` 15 L per minute– bag 0 mg– oral – at night in 5 mL – solution – 24-May-2010 Started	25-May-2010 26-May-2010 Started Started `ATE` 15 L per minute– bag 0 mg– oral – at night in 5 mL – solution – 24-May-2010 Started	25-May-2010 26-May-2010 Started Started `ATE` 15 L per minute– bag 0 mg– oral – at night in 5 mL – solution – 24-May-2010 Started

HSCIC Controlled Document

Page 45

TE 15 L per minute – Started 25-May-2010 ag 5 mL – solution – Started 24-May-2010 r dose – metered dose Started 24-May-2010	Col2
25-May-2010 Started 24-May-2010 Started `TE` 15 L per minute– ag r dose – metered dose 5 mL – solution – 24-May-2010 Started
	clopidogrel· fluticasone· tiotropium

Col1	Status	Start Date ▼
25-May-2010 26-May-2010 Started Started `RATE` 15 L per minute– er bag mg– oral – at night in 5 mL – solution – 24-May-2010 Started	25-May-2010 26-May-2010 Started Started `RATE` 15 L per minute– er bag mg– oral – at night in 5 mL – solution – 24-May-2010 Started	25-May-2010 26-May-2010 Started Started `RATE` 15 L per minute– er bag mg– oral – at night in 5 mL – solution – 24-May-2010 Started

Col1	Col2	Col3
	Status	Start Date ▼
25-May-2010 26-May-2010 Started Started `RATE` 15 L per minute– er bag mg– oral – at night mg in 5 mL – solution – 24-May-2010 Started	25-May-2010 26-May-2010 Started Started `RATE` 15 L per minute– er bag mg– oral – at night mg in 5 mL – solution – 24-May-2010 Started	25-May-2010 26-May-2010 Started Started `RATE` 15 L per minute– er bag mg– oral – at night mg in 5 mL – solution – 24-May-2010 Started

Col1	Col2	Col3
	Status	Start Date ▼
25-May-2010 26-May-2010 Started Started `RATE` 15 L per minute– er bag mg– oral – at night mg in 5 mL – solution – 24-May-2010 Started	25-May-2010 26-May-2010 Started Started `RATE` 15 L per minute– er bag mg– oral – at night mg in 5 mL – solution – 24-May-2010 Started	25-May-2010 26-May-2010 Started Started `RATE` 15 L per minute– er bag mg– oral – at night mg in 5 mL – solution – 24-May-2010 Started

HSCIC Controlled Document

Page 46

HSCIC Controlled Document

Reserving space for the look-ahead scroll bar achieves the following:

 The scroll bar and look-ahead notifications have fixed positions so there is no impact from the resizing or repositioning of the scroll

bar or the contents of the list as the notifications appear and disappear

 The look-ahead notification cannot overlap a medication in the list, so some of the risks associated with occlusion are mitigated

 A clearer definition of when a medication should appear in the notification can be achieved

User Feedback:

The guidance is supported by a user feedback study with nine health care staff that showed strong support for a mechanism of indicating that there are medications out of view. The look-ahead scroll bar is the example mechanism that was used in this study. The guidance is also supported by an iterative assessment of an interactive prototype.

Page 47

HSCIC Controlled Document

3.3.21 Defining LASB Interactions

Col1	Col2	Status	Start Date ▼
aspirin· isosorbide mononitrate	aspirin· isosorbide mononitrate	aspirin· isosorbide mononitrate	aspirin· isosorbide mononitrate
25-May-2010 26-May-2010 Started Started `RATE` 15 L per minute– er bag – oral – at night 24-May-2010 Started in 5 mL – solution –	25-May-2010 26-May-2010 Started Started `RATE` 15 L per minute– er bag – oral – at night 24-May-2010 Started in 5 mL – solution –	25-May-2010 26-May-2010 Started Started `RATE` 15 L per minute– er bag – oral – at night 24-May-2010 Started in 5 mL – solution –	25-May-2010 26-May-2010 Started Started `RATE` 15 L per minute– er bag – oral – at night 24-May-2010 Started in 5 mL – solution –

S S S	Col2	Col3
S S S	25-May-2010 tarted 24-May-2010 tarted 24-May-2010 tarted	25-May-2010 tarted 24-May-2010 tarted 24-May-2010 tarted
S S S	25-May-2010 tarted 24-May-2010 tarted 24-May-2010 tarted
S S S		fluticasone · tiotropium

Page 48

HSCIC Controlled Document

User Research:

The use of look-ahead notifications to support navigation has been explored extensively in user research studies, including a study with an interactive prototype. It has also been explored extensively through the assessment of design alternatives.

Page 49

HSCIC Controlled Document

3.3.22 Displaying LASB Notifications

Page 50

Col1	Col2	Col3
Drug Details	Status	Start Date ▼
6 more· metformin· glicazide· glyceryl trinitrate· dalteparin· aspirin· isosorbide mononitrate	6 more· metformin· glicazide· glyceryl trinitrate· dalteparin· aspirin· isosorbide mononitrate	6 more· metformin· glicazide· glyceryl trinitrate· dalteparin· aspirin· isosorbide mononitrate
25-May-2010 26-May-2010 Started Started oxygen 60% – inhalation gas –`RATE` 15 L per minute– continuous – with non re-breather bag temazepam– tablet –`DOSE` 20 mg– oral – at night co-amilofruse– 5 mgand40 mg in 5 mL – solution – 24-May-2010 Started	25-May-2010 26-May-2010 Started Started oxygen 60% – inhalation gas –`RATE` 15 L per minute– continuous – with non re-breather bag temazepam– tablet –`DOSE` 20 mg– oral – at night co-amilofruse– 5 mgand40 mg in 5 mL – solution – 24-May-2010 Started	25-May-2010 26-May-2010 Started Started oxygen 60% – inhalation gas –`RATE` 15 L per minute– continuous – with non re-breather bag temazepam– tablet –`DOSE` 20 mg– oral – at night co-amilofruse– 5 mgand40 mg in 5 mL – solution – 24-May-2010 Started
`DOSE` 5 mL– oral – once a day	`DOSE` 5 mL– oral – once a day	`DOSE` 5 mL– oral – once a day

Col1	Col2	Col3	Col4
Drug Details	Drug Details	Status	Start Date ▼
	2 more · benzydamine· lactulose· metoclopramide· morphine· metformin· glicazide· glyceryl trinitrate· dalteparin· aspirin· isosorbide mononitrate	2 more · benzydamine· lactulose· metoclopramide· morphine· metformin· glicazide· glyceryl trinitrate· dalteparin· aspirin· isosorbide mononitrate	2 more · benzydamine· lactulose· metoclopramide· morphine· metformin· glicazide· glyceryl trinitrate· dalteparin· aspirin· isosorbide mononitrate
25-May-2010 26-May-2010 Started Started oxygen 60% – inhalation gas –`RATE` 15 L per minute– continuous – with non re-breather bag temazepam– tablet –`DOSE` 20 mg– oral – at night co-amilofruse– 5 mgand40 mg in 5 mL – solution – 24-May-2010 Started	25-May-2010 26-May-2010 Started Started oxygen 60% – inhalation gas –`RATE` 15 L per minute– continuous – with non re-breather bag temazepam– tablet –`DOSE` 20 mg– oral – at night co-amilofruse– 5 mgand40 mg in 5 mL – solution – 24-May-2010 Started	25-May-2010 26-May-2010 Started Started oxygen 60% – inhalation gas –`RATE` 15 L per minute– continuous – with non re-breather bag temazepam– tablet –`DOSE` 20 mg– oral – at night co-amilofruse– 5 mgand40 mg in 5 mL – solution – 24-May-2010 Started	25-May-2010 26-May-2010 Started Started oxygen 60% – inhalation gas –`RATE` 15 L per minute– continuous – with non re-breather bag temazepam– tablet –`DOSE` 20 mg– oral – at night co-amilofruse– 5 mgand40 mg in 5 mL – solution – 24-May-2010 Started
`DOSE` 5 mL– oral – once a day	`DOSE` 5 mL– oral – once a day	`DOSE` 5 mL– oral – once a day	`DOSE` 5 mL– oral – once a day

Col1	aspirin · isosorbide mononitrate	Col3	Col4	Col5
		Status	Start Date ▼	Start Date ▼
25-May-2010 26-May-2010 Started Started –`RATE` 15 L per minute– ther bag mg– oral – at night mg in 5 mL – solution – 24-May-2010 Started	25-May-2010 26-May-2010 Started Started –`RATE` 15 L per minute– ther bag mg– oral – at night mg in 5 mL – solution – 24-May-2010 Started	25-May-2010 26-May-2010 Started Started –`RATE` 15 L per minute– ther bag mg– oral – at night mg in 5 mL – solution – 24-May-2010 Started	25-May-2010 26-May-2010 Started Started –`RATE` 15 L per minute– ther bag mg– oral – at night mg in 5 mL – solution – 24-May-2010 Started	25-May-2010 26-May-2010 Started Started –`RATE` 15 L per minute– ther bag mg– oral – at night mg in 5 mL – solution – 24-May-2010 Started

Col1	aspirin · isosorbide mononitrate	Col3
Drug Details	Status	Start Date ▼
25-May-2010 26-May-2010 Started Started oxygen 60% – inhalation gas –`RATE` 15 L per minute– continuous – with non re-breather bag temazepam– tablet –`DOSE` 20 mg– oral – at night co-amilofruse– 5 mgand40 mg in 5 mL – solution – 24-May-2010 Started	25-May-2010 26-May-2010 Started Started oxygen 60% – inhalation gas –`RATE` 15 L per minute– continuous – with non re-breather bag temazepam– tablet –`DOSE` 20 mg– oral – at night co-amilofruse– 5 mgand40 mg in 5 mL – solution – 24-May-2010 Started	25-May-2010 26-May-2010 Started Started oxygen 60% – inhalation gas –`RATE` 15 L per minute– continuous – with non re-breather bag temazepam– tablet –`DOSE` 20 mg– oral – at night co-amilofruse– 5 mgand40 mg in 5 mL – solution – 24-May-2010 Started
`DOSE` 5 mL– oral – once a day	`DOSE` 5 mL– oral – once a day	`DOSE` 5 mL– oral – once a day

HSCIC Controlled Document

Page 51

HSCIC Controlled Document

3.3.23 Selecting LASB Contents

Page 52

Col1	Col2	Col3	Col4	25-May-2010 24-May-2010 24-May-2010
oxygen 60% – inhalation gas –`RA` continuous – with non re-breather	oxygen 60% – inhalation gas –`RA` continuous – with non re-breather	`T` ba	`E` g	`E` g
co-amilofruse– 5 mgand40 mg in `DOSE` 5 mL– oral – once a day	co-amilofruse– 5 mgand40 mg in `DOSE` 5 mL– oral – once a day		5	5
salbutamol– 100 micrograms per dose 4 more · paracetamol· atenolol·	salbutamol– 100 micrograms per dose 4 more · paracetamol· atenolol·
salbutamol– 100 micrograms per dose 4 more · paracetamol· atenolol·	ose 4 more · paracetamol· atenolol·	t	iot	ropium· salbutamol

Col1	Col2	Col3	Col4	25-May-2010 24-May-2010 24-May-2010
oxygen 60% – inhalation gas –`RA` continuous – with non re-breather	oxygen 60% – inhalation gas –`RA` continuous – with non re-breather	`T` ba	`E` g	`E` g
co-amilofruse– 5 mgand40 mg in `DOSE` 5 mL– oral – once a day	co-amilofruse– 5 mgand40 mg in `DOSE` 5 mL– oral – once a day		5	5
salbutamol– 100 micrograms per dose 3 more· simvastatin· paracetam	salbutamol– 100 micrograms per dose 3 more· simvastatin· paracetam
salbutamol– 100 micrograms per dose 3 more· simvastatin· paracetam	ose 3 more· simvastatin· paracetam		lut	icasone· tiotropium

Col1	Col2	Col3	Col4	25-May-2010 24-May-2010 24-May-2010
oxygen 60% – inhalation gas –`RA` continuous – with non re-breather	oxygen 60% – inhalation gas –`RA` continuous – with non re-breather	`T` ba	`E` g	`E` g
co-amilofruse– 5 mgand40 mg in `DOSE` 5 mL– oral – once a day	co-amilofruse– 5 mgand40 mg in `DOSE` 5 mL– oral – once a day		5	5
salbutamol– 100 micrograms per dose 3 more· simvastatin· paracetam	salbutamol– 100 micrograms per dose 3 more· simvastatin· paracetam
salbutamol– 100 micrograms per dose 3 more· simvastatin· paracetam	ose 3 more· simvastatin· paracetam		lut	icasone· tiotropium

Col1	Col2	Col3	Col4	e 25-May-2010 24-May-2010 24-May-2010
salbutamol– 100 micrograms per inhaler –`DOSE` 2 puffs– inhaled –	salbutamol– 100 micrograms per inhaler –`DOSE` 2 puffs– inhaled –		o	o
salbutamol– 100 micrograms per inhaler –`DOSE` 2 puffs– inhaled –	salbutamol– 100 micrograms per inhaler –`DOSE` 2 puffs– inhaled –
co-amilofruse– 5 mgand40 mg in `DOSE` 5 mL– oral – once a day	co-amilofruse– 5 mgand40 mg in `DOSE` 5 mL– oral – once a day		5	5
co-amilofruse– 5 mgand40 mg in `DOSE` 5 mL– oral – once a day	co-amilofruse– 5 mgand40 mg in `DOSE` 5 mL– oral – once a day
oxygen 60% – inhalation gas –`RA` continuous – with non re-breather 3 more· simvastatin· paracetam	oxygen 60% – inhalation gas –`RA` continuous – with non re-breather 3 more· simvastatin· paracetam	`T`	`E`	`E`
oxygen 60% – inhalation gas –`RA` continuous – with non re-breather 3 more· simvastatin· paracetam	ontinuous – with non re-breather 3 more· simvastatin· paracetam	b	lut ag	icasone· tiotropium

HSCIC Controlled Document

Page 53

HSCIC Controlled Document

3.3.24 Displaying LASB Contents

Page 54

Col1	Col2
25-May-2010 Started 24-May-2010 Started er minute– metered dose solution – 24-May-2010 Started	25-May-2010 Started 24-May-2010 Started er minute– metered dose solution – 24-May-2010 Started
25-May-2010 Started 24-May-2010 Started er minute– metered dose solution – 24-May-2010 Started
	fluticasone· tiotropium

HSCIC Controlled Document

Page 55

HSCIC Controlled Document

3.3.25 Formatting LASB Contents

Col1	– RATE 15 L per minute – Started 25-May-2010 ther bag mg in 5 mL – solution – Started 24-May-2010 ms per dose – metered dose Started 24-May-2010 haled –

	enolol#paracetamol#atenolol#ramipril#clopidogrel#fluticasone#tiotropium

Col1	Col2
25-May-2010 Started 24-May-2010 Started er minute– metered dose solution – 24-May-2010 Started	25-May-2010 Started 24-May-2010 Started er minute– metered dose solution – 24-May-2010 Started
25-May-2010 Started 24-May-2010 Started er minute– metered dose solution – 24-May-2010 Started
	fluticasone· tiotropium·

Page 56

HSCIC Controlled Document

3.3.26 Drug Names in the LASB

Col1	Col2
25-May-2010 Started 24-May-2010 Started oxygen 60% – inhalation gas –`RATE` 15 L per minute– continuous – with non re-breather bag salbutamol– 100 micrograms per dose – metered dose inhaler –`DOSE` 2 puffs– inhaled – co-amilofruse– 5 mgand40 mg in 5 mL – solution – `DOSE` 5 mL– oral – once a day 24-May-2010 Started	25-May-2010 Started 24-May-2010 Started oxygen 60% – inhalation gas –`RATE` 15 L per minute– continuous – with non re-breather bag salbutamol– 100 micrograms per dose – metered dose inhaler –`DOSE` 2 puffs– inhaled – co-amilofruse– 5 mgand40 mg in 5 mL – solution – `DOSE` 5 mL– oral – once a day 24-May-2010 Started
25-May-2010 Started 24-May-2010 Started oxygen 60% – inhalation gas –`RATE` 15 L per minute– continuous – with non re-breather bag salbutamol– 100 micrograms per dose – metered dose inhaler –`DOSE` 2 puffs– inhaled – co-amilofruse– 5 mgand40 mg in 5 mL – solution – `DOSE` 5 mL– oral – once a day 24-May-2010 Started
four times a day as require	d 3 more · atenolol· ramipril· clopidogrel· fluticasone· tiotropium

Page 57

HSCIC Controlled Document

3.3.27 Formatting LASB Notifications

Page 58

HSCIC Controlled Document

3.3.28 Displaying a LASB for Past Medications

Discontinued digoxin – tablet – DOSE 125 micrograms – oral – once a day	Col2
methyldopa – tablet –`DOSE` 250 mg – oral – twice a day Discontinued Completed Completed hydrochlorothiazide – tablet –`DOSE` 100 mg – oral – 4 times a day furosemide – tablet –`DOSE` 40 mg – oral – once a day	methyldopa – tablet –`DOSE` 250 mg – oral – twice a day Discontinued Completed Completed hydrochlorothiazide – tablet –`DOSE` 100 mg – oral – 4 times a day furosemide – tablet –`DOSE` 40 mg – oral – once a day
	3 more

Page 59

HSCIC Controlled Document

3.3.29 Providing a Grouping Control

Page 60

HSCIC Controlled Document

3.3.30 Supporting Grouping

Page 61

HSCIC Controlled Document

Page 62

HSCIC Controlled Document

3.3.31 Displaying Group Headings

Page 63

HSCIC Controlled Document

Page 64

HSCIC Controlled Document

3.3.32 Collapsing Groups

Page 65

HSCIC Controlled Document

Page 66

HSCIC Controlled Document

3.3.33 Combining Groups to Avoid Duplication

Page 67

HSCIC Controlled Document

3.3.34 Supporting Sorting

Section 3.3.15 includes guidance on the default sort order of a list of current medications and section 3.3.18 includes guidance on the default sort order of past medications.

Status First Administration ▼ Not Started 29-May-2010	Status	First Administration ▼
27-May-2010 Started	27-May-2010 Started	27-May-2010 Started
25-May-2010 Started	25-May-2010 Started	25-May-2010 Started

Page 68

HSCIC Controlled Document

3.3.35 Supporting Levels of Detail

Page 69

HSCIC Controlled Document

3.3.36 Supporting Selection and Action

Page 70

HSCIC Controlled Document

Page 71

HSCIC Controlled Document

3.3.37 Providing Context Menus

temazepam – tablet – DOSE 20 mg – oral – at night Started 26-May-2010	Col2	Col3
oxygen 60% – inhalation gas –`RATE` 15 L per minute– continuous – with non re-breather bag 25-May-2010 Started	oxygen 60% – inhalation gas –`RATE` 15 L per minute– continuous – with non re-breather bag 25-May-2010 Started	oxygen 60% – inhalation gas –`RATE` 15 L per minute– continuous – with non re-breather bag 25-May-2010 Started
co-amilofruse– 5 mgand40 mg in 5 mL – solution – `DOSE` 5 mL– oral – once a day 24-May-2010 Started Action 1	co-amilofruse– 5 mgand40 mg in 5 mL – solution – `DOSE` 5 mL– oral – once a day 24-May-2010 Started Action 1	co-amilofruse– 5 mgand40 mg in 5 mL – solution – `DOSE` 5 mL– oral – once a day 24-May-2010 Started Action 1
co-amilofruse– 5 mgand40 mg in 5 mL – solution – `DOSE` 5 mL– oral – once a day 24-May-2010 Started Action 1	Action 1	Action 1
salbutamol– 100 micrograms per dose – metered dose inhaler –`DOSE` 2 puffs– inhaled – four times a day as required	Started 24-Ma Action 2 Action 3 Action 4	y-2010
salbutamol– 100 micrograms per dose – metered dose inhaler –`DOSE` 2 puffs– inhaled – four times a day as required	Action 5 Action 6 Action 7	Action 5 Action 6 Action 7

Page 72

HSCIC Controlled Document

3.3.38 Providing Access to Medication Details

Page 73

HSCIC Controlled Document

3.4 Rationale Summary

This section summarises the principles behind the rationale for all guidance points in this document.

General Principles:

Provide support for legibility
Mitigate risks of incorrect selection and misinterpretation

Usability Principles:

Minimise the use of embellishments (for example, bold, colour, fonts, font sizes, italics,

separators and symbols)

Minimise instances of each type of embellishment within a reading unit
Consistent use of specific embellishments within and preferably between user-interface

contexts or ‘views’

Use words instead of symbols where it is important for removing ambiguity

Existing Standards:

NHS NPfIT – ePrescribing Functional Specification {R9}
NHS NPfIT – Guidelines for the Design and Presentation of Medication Elements Required

in Electronic Prescribing or Medication Ordering Systems {R15}

Institute for Safe Medication Practices (ISMP) (US) – Draft Guidelines for Safe Electronic

Communication of Medication Orders [7]

Evolving Standards:

Standard set of information needed to safely describe a medication

7 ISMP – ISMP MedicationSafetyAlert! – It’s Time for Standards to Improve Safety with Electronic Communication of Medication Orders – Draft Guidelines for Safe Electronic Communication of Medication Orders {R16} : http://www.ismp.org/Newsletters/acutecare/articles/20030220.asp

Page 74

HSCIC Controlled Document

4 DOCUMENT INFORMATION

4.1 Terms and Abbreviations

ACBS Advisory Committee on Borderline Substances

AMP Actual Medicinal Product

CATR Clinical Authority to Release

CSG Clinical Safety Group

CSMS Clinical Safety Management System

CUI Common User Interface

dm+d Dictionary of Medicines and Devices

HDU High Dependency Unit

ISMP The Institute for Safe Medication Practices

IUD Intrauterine Device

LASB Look-Ahead Scroll Bar

NHS National Health Service

NHS CFH NHS Connecting for Health

NPfIT National Programme for IT

NPSA National Patient Safety Agency

OTC Over the Counter

PGD Patient Group Direction

PODs Patient’s Own Drugs

TFN Trade Family Name

TPN Total Parental Nutrition

TTO To Take Out

UI User Interface

VTM Virtual Therapeutic Moiety

W3C World Wide Web Consortium

Table 6: Terms and Abbreviations

Page 75

HSCIC Controlled Document

4.2 Definitions

NHS Entity Within this document, defined as a single NHS organisation or group that is operated within a single technical infrastructure environment by a defined group of IT administrators.

The Authority The organisation implementing the NHS National Programme for IT (currently NHS Connecting for Health).

Current best practice Current best practice is used rather than best practice, as over time best practice guidance may change or be revised due to changes to products, changes in technology, or simply the additional field deployment experience that comes over time.

Generic drug name This can be a single drug name that refers to a single active ingredient or it can be multiple active ingredients that are prescribed as one drug. In the structure of the dm+d {R10}, this generally equates to a Virtual Therapeutic Moiety (VTM)

Brand name A brand name for a product containing medication. A brand name may be associated with many products. In some cases, the same brand name may be associated with different generic drugs. Future versions of the dm+d {R10} are expected to include a separate entity for brand name, known as Trade Family Name (TFN). In the meantime, the brand name is part of the Actual Medicinal Product (AMP)

Table 7: Definitions

4.3 Nomenclature

This section shows how to interpret the different styles used in this document to denote various types of information.

4.3.1 Body Text

Code Monospace

Script

Other markup languages

Interface dialog names Bold

Field names

Controls

Folder names Title Case

File names

Table 8: Body Text Styles

4.3.2 Cross References

Current document – sections Section number only

Current document – figures/tables Caption number only

Other project documents Italics and possibly a footnote

Publicly available documents Italics with a footnote

External Web-based content Italics and a hyperlinked footnote

Table 9: Cross Reference Styles

Page 76

HSCIC Controlled Document

4.4 References

R1. NHS CUI Programme – Design Guide Entry – Medications Management – Medication Views 2.0.0.0

R2. NHS CUI Programme – Medications Management – Medication Line – User Interface Design Guidance

R3. NPSA – Safety in doses: medication safety incidents in the NHS http://www.npsa.nhs.uk/nrls/alerts-and-directives/directives-guidance/safety-in-doses/

R4. Medication Errors – Causes, Prevention, and Risk Management – Cohen M R (Ed) – Jones and Bartlett Publishers

R5. To Err is Human – Building a Safer Health System – Kohn L, Corrigan J, Donaldson M – Washington, DC: National Academy Press, 2000

2.0.0.0

2007

2004

2000

R6. Understanding Patient Safety – Wachter R M – The McGraw-Hill Companies, Inc, 2008 2008

R7. Healthcare Commission Patient Survey – Room for Review: a Guide to Medication Review 2004

R8. National service framework for older people – Department of Health http://www.dh.gov.uk/en/publicationsandstatistics/publications/publicationspolicyandguidance/DH_4 003066

R9. NHS NPfIT – ePrescribing Functional Specification http://www.connectingforhealth.nhs.uk/newsroom/news-stories/eprescfunctspec

R10. NHS – dictionary of medicines + devices http://www.dmd.nhs.uk/

R11. NHS CUI Programme – Medications Management – Drug Administration – User Interface Design Guidance

2001

1.0

Release 2.3

3.0.0.0

R12. The Visual Display of Quantitative Information – Tufte E, 2001, Cheshire, CT – Graphics Press Second Edition 2001

R13. Web Content Accessibility Guidelines 1.0 – W3C Recommendation 5-May-1999 http://www.w3.org/TR/WAI-WEBCONTENT/

R14. Techniques for Accessibility Evaluation and Repair Tools – W3C Working Draft – 26 April 2000 – Technique 2.2.1 [priority 3] Test the colour attributes of the following elements for visibility: http://www.w3.org/TR/AERT#color-contrast

R15. NHS NPfIT – Guidelines for the Design and Presentation of Medication Elements Required in Electronic Prescribing or Medication Ordering Systems – NPfIT-EP-DB-0003.01

R16. ISMP – ISMP MedicationSafetyAlert! – It’s Time for Standards to Improve Safety with Electronic Communication of Medication Orders – Draft Guidelines for Safe Electronic Communication of Medication Orders http://www.ismp.org/Newsletters/acutecare/articles/20030220.asp

Table 10: References

1999

2000

2005

20-Feb-2003

Page 77

HSCIC Controlled Document

APPENDIX A REFERENCE SUMMARY OF GUIDANCE

MEDv-020 MEDv-141 Visual Summary:

Col1	sentence	tabula

xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz
xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz
xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz
xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz

MEDv-020 3.3.1 Present medications as lines of text within rows in a tabular format where each row represents one medication

MEDv-142 Visual Summary:

minimise the display of blank cells for some row n a separate column)	Col2
xxxx– xxxx - xxxx xxxx– xxxx - xxxx xxxx– xxxx - xxxx xxxx– xxxx - xxxx yyyy zzzz yyyy zzzz yyyy zzzz yyyy zzzz	xxxx– xxxx - xxxx xxxx– xxxx - xxxx xxxx– xxxx - xxxx xxxx– xxxx - xxxx yyyy zzzz yyyy zzzz yyyy zzzz yyyy zzzz

	space

MEDv-142 3.3.2 When the list is scrolled to the end, display a space at the bottom of the list with a height equivalent to a line of text

MEDv-021 Visual Summary:

Col1	no strong

xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz
xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz
xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz
xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz

MEDv-021 3.3.3 Avoid the use of strong grids and strong vertical lines. (Use subtle methods to support distinguishing between rows in the list)

MEDv-022, MEDv-142 to MEDv-145 Visual Summary:

MEDv-143 3.3.4 Use at least alternate row shading or lines between rows

MEDv-022 3.3.4 Use subtle alternate row shading

MEDv-144 3.3.4 When using alternate row shading, ensure that colour and brightness of the background does not interfere with the readability of the foreground text

MEDv-145 3.3.4 Supplement alternate shading with 1 point pale lines between rows

MEDv-023 Visual Summary:

Col1	Col2	icons	Col4

xxxx– xxxx - xx	A	B	yyyy zzzz
xxxx– xxxx - xx yyyy zzzz B	xxxx– xxxx - xx yyyy zzzz B	xxxx– xxxx - xx yyyy zzzz B	xxxx– xxxx - xx yyyy zzzz B
xxxx– xxxx - xx	A	yyyy zzzz	yyyy zzzz

MEDv-023 3.3.5 Support the display of icons following the text of the Drug Details column in the Medications List View

Page 78

HSCIC Controlled Document

MEDv-146 Visual Summary:

aaaa	bbbb	cccc
empty list message	empty list message	empty list message

MEDv-146 3.3.6 Display a message when a list is empty (for example, when there are no current medications)

MEDv-147 to MEDv-150 Visual Summary:

mandatory columns

MEDv-147 3.3.7 Provide a column that contains status information including information that defines whether the medication is ‘current’ or ‘past’

MEDv-148 3.3.7 Provide a column that contains drug details according to Medication Line guidance

MEDv-149 3.3.7 When displaying current medications, provide a column that contains an initiation date (such as the date of the first planned administration). The examples in this document show a Start Date column.

MEDv-150 3.3.7 When displaying past medications, provide a column that contains a stop date (such as the date of the last administration or the date that the medication was discontinued). The examples in this document show an End Date column.

MEDv-151 to MEDv-154 Visual Summary:

Col1	Col2	Col3
Start	Start	End

MEDv-151 3.3.8 When an end date column is displayed, place a start date column before (to the left of) the end date column

MEDv-152 3.3.8 When an end date column is displayed, and there is no duration column, place a start date column adjacent to the end date column

MEDv-153 3.3.8 Use fixed width columns for dates

MEDv-154 3.3.8 Maintain consistent placement of date columns relative to one another and relative to the Drug Details column in both current and past medications

MEDv-150 toMED-152 Visual Summary:

First Administration

Last Administration

MEDv-155 3.3.9 Label columns with text that describes the contents unambiguously and succinctly (such as, ‘Status’, ‘Date Prescribed’ or ‘First Administration’)

MEDv-156 3.3.9 Use a unique heading for each column

MEDv-157 3.3.9 When combining two attributes that have the same data type (such as dates), include labels for both attributes in the column heading

Page 79

HSCIC Controlled Document

MEDv-027, MEDv-158 Visual Summary:

Start and End Dates Start zzzz

End zzzz

Start zzzz

End zzzz

MEDv-027 3.3.10 Allow columns to contain more than one attribute for a single medication

MEDv-158 3.3.10 When combining two attributes that have the same data types (such as dates), include labels for both attributes within the cell

MEDv-159 to MEDv-161 Visual Summary:

aaaa	bbbb	cccc
relative widths

MEDv-159 3.3.11 Maintain the relative proportions of columns such that the Drug Details column is the widest

MEDv-160 3.3.11 Avoid the need for horizontal scrolling by limiting the number of columns visible at any one time

MEDv-161 3.3.11 Define minimum widths for all columns

Current Past

Status Completed

Discontinued

MEDv-162 to MEDv-165 Visual Summary:

Status Started

Not Started

Suspended

MEDv-162 3.3.12 Ensure that all medications have a status value and the status cannot be blank

MEDv-163 3.3.12 Limit status descriptions to short phrases, preferably no more than two words

MEDv-164 3.3.12 Allow status to be supplemented with additional information (such as pharmacy verified).

MEDv-165 3.3.12 Use the status description to differentiate between medications that have no recorded administration events and those that have.

Started

Not Started

Suspended

Completed

Discontinued

MEDv-166 to MEDv-172 Visual Summary:

Current

Past

MEDv-166 3.3.13 Support a status of ‘suspended’ and include medications with this status in current medications

MEDv-167 3.3.13 Assign a status of ‘Started’ to medications that have an administration event recorded and have further scheduled administrations

MEDv-168 3.3.13 Assign a status of ‘Not Started’ to medications that have administration scheduled and a start date in the future

MEDv-169 3.3.13 Assign a status of ‘Suspended’ to medications that are marked as not to be administered but which are intended to be resumed at a later date

MEDv-170 3.3.13 Assign a status of ‘Completed’ to medications that have administration events recorded according to their schedule (within tolerances) and have an end date in the past

MEDv-171 3.3.13 Assign a status of ‘Discontinued’ to medications that were stopped on a date that preceded one or more of the scheduled administrations

Page 80

HSCIC Controlled Document

MEDv-172 3.3.13 Define medications with a status of either ‘Started’, ‘Not Started’ or ‘Suspended’ as current medications

MEDv-173 3.3.13 Define medications with a status of either ‘Completed’ or ‘Discontinued’ as past medications

MEDv-024, MEDv-025, MEDv-042 Visual Summary:

xxxx – xxxx - xxxx yyyy zzzz	Col2
xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz
xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz
xxxx– xxxx - xxxx	yyyy zzzz
	Important S

MEDv-024 3.3.14 Use visual design to draw attention to suspended medications

MEDv-025 3.3.14 Use visual design to distinguish a list of current medications from a list of past medications

MEDv-042 3.3.14 Display the status of each medication in bold

MEDv-062 to MEDv-067, MEDv-172 Visual Summary:

MEDv-063 3.3.15 Provide buttons for displaying current and past medications respectively in the Medications List View and label the buttons ‘Current’ and ‘Past’

MEDv-062 3.3.15 Present the Medications List View with Current selected by default

MEDv-064 3.3.15 Use the visual formatting of the Current and Past buttons to indicate which is currently selected

MEDv-065 3.3.15 Do not allow Current and Past buttons to be selected simultaneously

MEDv-174 3.3.15 Ensure that either the Current or the Past button is selected at any one time

MEDv-066 3.3.15 Supplement the Past button in the Medications List view with a drop-down control for displaying, selecting and applying a filter on the past medications view

MEDv-067 3.3.15 Include an option for displaying all past medications in the drop-down control

Current

MEDV-099, MEDV-173 Visual Summary:

Drug Details	Col2	xxxx	Start ▼
		default sort	default sort
	first column	first column	first column

MEDv-099 3.3.16 By default, present current medications sorted reverse chronologically by a starting date such that the most recent is first (top) in the list

MEDv-173 3.3.16 When displaying current medications, place the drug details in the first (furthest left) column

Current

MEDv-074, MEDv-075, MEDv-077, MEDv-175 Visual Summary:

MEDv-074 3.3.17 When displaying current medications, display a notification for medications that have been completed or discontinued within a specified time interval from the current time

MEDv-075 3.3.17 Clearly display the time interval within the recent past notification

Page 81

HSCIC Controlled Document

MEDv-077 3.3.17 Display a count of the number of recently past medications within the recent past notification in the medication list

MEDv-174 3.3.17 Use formatting to distinguish the recent past notifications from medications in the list

Past

MEDv-100, MEDv-173 Visual Summary:

Status	Col2	Drug Details	End ▼
		default sort	default sort
	first column	first column	first column

MEDv-100 3.3.18 By default, sort medications reverse chronologically by end date (or equivalent) such that the most recent is first (top) when the filter is set to ‘Past’ in the Medications List View

MEDv-175 3.3.18 When displaying past medications, place the status column first (furthest left) and the Drug Details column second

Past

MEDv-068 to MEDv-073 Visual Summary:

MEDv-069 3.3.19 When a filter is applied to past medications in the Medications List View, the Past button should indicate that it is currently selected

MEDv-070 3.3.19 When a filter is applied to past medications in the Medications List View, display a filter notification at the top of the list below the column headings and above the scroll bar (thus ‘pushing’ the list of medications down a line)

MEDv-068 3.3.19 When a filter notification is displayed, include a control for removing the filter within that notification

MEDv-071 3.3.19 Display a description of the filter in use within the filter notification in the medications list

MEDv-072 3.3.19 Include a count of the number of medications displayed and a count of the total (unfiltered) number of past medications in a filter notification

MEDv-073 3.3.19 Clearly label the counts (number of medications displayed and total unfiltered number) with text that allows them to be differentiated

MEDv-176 3.3.19 When a filter is applied to past medications in the Medications List View, the Past button should indicate that it is currently selected

MEDv-177 to MEDv-179 Visual Summary:

Col2	Col3	Col4	Col5




reserved space	reserved space	reserved space	reserved space

MEDv-177 3.3.20 When displaying a list of (current or past) medications and the scroll bar is active because the list is longer than the space available to display them, provide a clear indication that there are medications out of view

MEDv-178 3.3.20 When displaying current medications, supplement the standard scroll bar with notifications that display the names of drugs that are out of view. This document refers to this kind of scroll bar as a look-ahead scroll bar (LASB)

MEDv-179 3.3.20 When displaying a LASB, reserve a space at the top and bottom of the list for look-ahead notifications

Page 82

HSCIC Controlled Document

MEDv-180 3.3.20 Use a pale solid background colour for the space reserved for look-ahead notifications that is sufficient to distinguish the space from the background of the list

MEDv-181 3.3.20 When grouping is applied and there is a collapsed group out of view, display drug names in the lookahead scroll bar for any drug that is out of view irrespective of whether it is within a collapsed group or an expanded group

MEDv-058, MEDv-059, MEDv-177 Visual Summary:

Col1	Col2	Col3
ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx yyyy zzzz yyyy zzzz yyyy zzzz	ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx yyyy zzzz yyyy zzzz yyyy zzzz	ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx yyyy zzzz yyyy zzzz yyyy zzzz

MEDv-058 3.3.21 Update the look-ahead notifications dynamically in response to scrolling

MEDv-059 3.3.21 Allow the look-ahead notification to change width dynamically to accommodate its contents up to the available width

MEDv-182 3.3.21 Do not allow the look-ahead notification to be used for navigation by clicking on areas of the notification, such as drug names or counts

MEDv-043 to MEDv045 Visual Summary:

alignment

Col1	Col2	Col3	Col4	Col5
aaaa	bbbb	bbbb	cccc	cccc

ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx yyyy zzzz yyyy zzzz yyyy zzzz	ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx yyyy zzzz yyyy zzzz yyyy zzzz	ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx yyyy zzzz yyyy zzzz yyyy zzzz	ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx yyyy zzzz yyyy zzzz yyyy zzzz

MEDv-044 3.3.22 Restrict the look-ahead notifications to a single line each

MEDv-043 3.3.22 The look-ahead notifications should be clearly joined to the ‘up’ and ‘down’ arrow controls of the scroll bar respectively

MEDv-045 3.3.22 Do not place controls or other notifications such that they separate the look-ahead notification from the

visible list

MEDv-049, MEDv-181 Visual Summary:

edications List View	Col2
aaa– xxxx - xxxx	l
bbb– xxxx - xxxx	bbb– xxxx - xxxx
ccc– xxxx - xxxx	ccc– xxxx - xxxx
ccc– xxxx - xxxx	l
ddd– xxxx - xxxx	ddd– xxxx - xxxx
eee– xxxx - xxxx	eee– xxxx - xxxx
fff– xxxx - xxxx	fff– xxxx - xxxx

MEDv-049 3.3.23 The order of both the items in the look-ahead notification and the Medications List View should always be the same

MEDv-183 3.3.23 If any of the drug name text (other than letter ascenders and descenders) is obscured by the boundaries of the list, include that drug in the look-ahead notification.

Page 83

HSCIC Controlled Document

MEDv-048, MEDv-052, MEDv-053, MEDv-055 Visual Summary:

Col1	Col2	aaa ·	bbb
ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx yyyy zzzz yyyy zzzz yyyy zzzz	ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx yyyy zzzz yyyy zzzz yyyy zzzz	ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx yyyy zzzz yyyy zzzz yyyy zzzz	ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx yyyy zzzz yyyy zzzz yyyy zzzz
	2 more· kkk· jjj· iii· ggg· fff	2 more· kkk· jjj· iii· ggg· fff	2 more· kkk· jjj· iii· ggg· fff

MEDv-048 3.3.24 The look-ahead notification is populated from right to left such that the next drug in the list appears closest to the scroll bar

MEDv-052 3.3.24 When there are more items than can be displayed in the look-ahead notification for current medications, display as many as possible and end the list with a count of the remaining items that could not be displayed

MEDv-053 3.3.24 When a count is displayed in a look-ahead notification and one or more of the medications included in that count have decision support alerts, display a decision support alert icon next to the count

MEDv-055 3.3.24 When displaying current medications only, show drug names and decision support alert icons in the look-ahead notification

MEDv-056, MEDv-179, MEDv-180 Visual Summary:

MEDv-056 3.3.25 Use a delimiter that is unlikely to be interpreted as a character or number (such as a black dot ‘●’), with a space either side to separate drug names and to separate the count from drug names

MEDv-184 3.3.25 Do not use leading or training delimiters

MEDv-185 3.3.25 Do not include additional text or formatting to indicate grouping in the look-ahead notifications

MEDv-050, MEDv-051 Visual Summary:

MEDv-050 3.3.26 Where exceptionally long drug names require more space than is available in a look-ahead notification, display a count (as for past medications) instead

MEDv-051 3.3.26 Do not truncate or abbreviate drug names in the look-ahead notification

MEDv-184 to MEDv-186 Visual Summary:

MEDv-186 3.3.27 Display drug names in bold and in black text by default

MEDv-187 3.3.27 Display counts and descriptive text (such as ‘more’) in normal weight font

MEDv-188 3.3.27 Use a light solid background colour for the notifications that is both sufficiently different from the colour in the space reserved for notifications and sufficiently different from the black text in the notification

MEDv-189 3.3.27 Do not use a border in a dark colour or with a weight greater than 1 point for a look-ahead notification

Past Current

MEDv-054 Visual Summary:

Col1	2 more
ppp– xxxx - xxxx qqq– xxxx - xxxx ooo– xxxx - xxxx	ppp– xxxx - xxxx qqq– xxxx - xxxx ooo– xxxx - xxxx
	4 more

Col1	Col2	aaa · bbb
ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx	ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx	ddd– xxxx - xxxx eee– xxxx - xxxx ccc– xxxx - xxxx
	2 more· ggg· fff	2 more· ggg· fff

MEDv-054 3.3.28 When displaying past medications only, display counts in the look-ahead notification and not drug names.

Page 84

HSCIC Controlled Document

MEDv-084, MEDv-085, MEDv185 Visual Summary:

MEDv-084 3.3.29 Provide a drop-down list for displaying, selecting and applying a grouping to the medications list

MEDv-085 3.3.29 Label the grouping control ‘Group by’

MEDv-190 3.3.29 Include an option in the drop-down list to set the grouping to ‘None’

Group A

yyyy zzzz

MEDv-083, MEDv-087, MEDv-188 to MEDv-190 Visual Summary:

xxxx - xxxx - xxxx

Group B

xxxx - xxxx - xxxx yyyy zzzz

xxxx - xxxx - xxxx

yyyy zzzz

MEDv-083 3.3.30 Present the Medications List View with no grouping active by default

MEDv-087 3.3.30 Retain the column sort order in the Medications List View when grouping is applied

MEDv-191 3.3.30 Display groups expanded by default

MEDv-192 3.3.30 Re-start alternate row shading at the beginning of each group. (Alternate row shading is not needed if there is only one medication in each group)

MEDv-193 3.3.30 When a grouping is selected in the grouping control, ensure that at least one group heading is visible in the newly grouped list

MEDv-086, MEDv088, MEDv-090, MEDv-091 Visual Summary:

Col1	Tablet
	xxxx– xxxx - xxxx yyyy zzzz
	(No Form Specified)
	xxxx– xxxx - xxxx yyyy zzzz
	xxxx– xxxx - xxxx yyyy zzzz

MEDv-086 3.3.31 Display clear and prominent headings for each group category

MEDv-090 3.3.31 Do not display group headings for empty groups

MEDv-091 3.3.31 Provide ‘null’ groups where necessary to support the display of medications that do not have a value for the attribute being used to group the medications

MEDv-194 3.3.31 Display the label for a ‘null’ group heading in brackets

MEDv-195 3.3.31 Display ‘null’ groups at the top of the list of groups

MEDv-092, MEDv-089, MEDv-092 Visual Summary:

MEDv-092 3.3.32 Provide controls for expanding and collapsing individual groups. Place these controls at the beginning of the group heading

MEDv-089 3.3.32 When a group is collapsed, supplement the group heading with a number representing a count of medications within that group

MEDv-196 3.3.32 Support the selection of group headings and the display of a context menu that includes options for collapsing and expanding all columns

Page 85

HSCIC Controlled Document

MEDv-193, MEDv-194 Visual Summary:

MEDv-197 3.3.33 When one or more medications belong to more than one group (such as analgesic and non-steroidal anti-inflammatory), create a new group and label it with the group names combined (such as ‘Analgesic, Non-steroidal Anti-inflammatory’)

MEDv-198 3.3.33 Display each medication in only one group (do not duplicate medications so that they can be displayed in more than one group)

MEDv-199 3.3.33 When combining group names, display the names in the same order that they would appear in a list that is sorted by that attribute

MEDv-200 3.3.33 When combining group names, separate the labels with a semi-colon

formatting

MEDv-101 to MEDv-106 Visual Summary:

Col1	Col2	Col3	Col4
aaaa	Start▼	Start▼	Start▼
aaaa	Start▼
zzzz yyyy xxxx aaaa aaaa aaaa	zzzz yyyy xxxx aaaa aaaa aaaa

MEDv-101 3.3.34 Allow the sort order of a list in the medications list to be changed by clicking on a column heading

MEDv-102 3.3.34 Allow the sort order of a list in the Medications List View to be reversed by clicking on the column heading for the column with the active sort applied

MEDv-103 3.3.34 Use formatting of the column heading to clearly indicate the column to which the sort order is currently applied

MEDv-104 3.3.34 Use an icon or symbol in the column heading to indicate the column by which the data is sorted and the direction of the sort

MEDv-105 3.3.34 When the sort order is changed from the default to another attribute in the Medications List View, retain the default as a secondary sort order

MEDv-195 Visual Summary:

xxxx – xxxx - xxxx yyyy	Col2
xxxx– xxxx - xxxx yyyy	xxxx– xxxx - xxxx yyyy
xxxx– xxxx - xxxx yyyy
xxxx– xxxx - xxxx yyyy	xxxx– xxxx - xxxx yyyy

MEDv-201 3.3.35 Provide a control that allows the type and quantity of information displayed to be changed such that the rows and columns may change in number and be presented with a different layout

MEDv-122 to MEDv-127 Visual Summary:

MEDv-202 3.3.36 Ensure that there are no medications selected by default when a list is opened

MEDv-122 3.3.36 Support click (or keyboard selection using the spacebar) to select a medication in the list

MEDv-123 3.3.36 Clearly highlight selected medications in the medication list

Page 86

HSCIC Controlled Document

MEDv-124 3.3.36 Maintain the selection of a medication when switching between views of a patient’s medications (such that a medication selected in a medication list is automatically selected when switching to the Drug Administration view)

MEDv-125 3.3.36 Maintain the selection of a medication when applying or changing a grouping or a sort order and ensure that the selection remains visible

MEDv-126 3.3.36 Support the selection of multiple items using CTRL and click for discrete selections, and SHIFT and click for contiguous selections

MEDv-127 3.3.36 Support keyboard-only equivalents such as SHIFT and arrow key for contiguous selection and the CTRL and SPACEBAR to toggle select and deselect when making non-continuous selections

MEDv-203 3.3.36 When an action is applied to more than one medication, display a summary of the selected

MEDv-128 to MEDv133 Visual Summary:

he user to complete the action	Col2	Col3
xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz
xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz
xxxx– xxxx - xxxx yyyy zzzz ~~Action 1~~	xxxx– xxxx - xxxx yyyy zzzz ~~Action 1~~	xxxx– xxxx - xxxx yyyy zzzz ~~Action 1~~
xxxx– xxxx - xxxx yyyy zzzz ~~Action 1~~	yyyy zzzz ~~Action 1~~	yyyy zzzz ~~Action 1~~
xxxx– xxxx - xxxx	yyyy zzzz Action 2
	Action 3

MEDv-128 3.3.37 Support the display of a context menu for selected medications in the Medications List View (for example, by right-clicking)

MEDv-129 3.3.37 In the context menu for selections in the Medications List View, provide appropriate actions and options

MEDv-130 3.3.37 In the context menu for selections in the Medications List View, support actions with icons where appropriate

MEDv-131 3.3.37 In the context menu for selections in the Medications List View, grey out actions that are unavailable or disallowed for one or more of the current selections

MEDv-132 3.3.37 In the context menu for selections in the Medications List View, prioritise frequently used actions by placing them higher in the list

MEDv-133 3.3.37 In the context menu for selections in the Medications List View, group similar options so that direct actions, actions that permit addition of information and actions that display more information are each grouped together

MEDv-135, MEDv-136 Visual Summary:

xxxx – xxxx - xxxx yyyy zzzz	Col2	Col3
xxxx– xxxx - xxxx yyyy zzzz	xxxx– xxxx - xxxx yyyy zzzz
xxxx–	xxxx - xxxx yyyy zzzz	xxxx - xxxx yyyy zzzz
xxxx–	xxxx - xxxx yyyy zzzz	xxxx - xxxx yyyy zzzz
xxxx–	xxxx - xxxx yyyy zzzz ~~Detailed informati~~	xxxx - xxxx yyyy zzzz ~~Detailed informati~~

MEDv-135 3.3.38 In the context menu for selections in the Medications List View, provide an option for displaying all details for the selected medication

MEDv-136 3.3.38 Support accessing all details for one medication by double-clicking the medication line in the Medications List View

Table 11: Reference Summary of Guidance

Page 87

HSCIC Controlled Document

REVISION AND SIGNOFF SHEET

Change Record

28-Oct-2008 Sarah Parker 0.0.0.1 Initial draft for review/discussion

05-Nov-2008 Sarah Parker 0.0.0.2 First draft for copyedit and customer review

06-Nov-2008 Manuela Perr 0.0.1.0 Raised to Working Baseline

10-Nov-2008 Mick Harney 0.0.1.1 Copyedited

18-Dec-2008 Sarah Parker 0.0.1.2 Updates to address copyedit and SA comments

09-Jan-2009 Mick Harney 0.0.1.3 Copyedit changes since Working Baseline. Last questions for Sarah.

17-Feb-2009 Sarah Parker 0.0.1.4 Responses to copyedit comments and further revisions in response to SA requests for further changes.

20-Feb-2009 Mick Harney 0.0.1.5 Copyedit pass. Remaining questions flagged.

23-Feb-2009 Sarah Parker 0.0.1.6 Responses to copyedit comments

23-Feb-2009 Mick Harney 0.1.0.0 Raised to Baseline Candidate

05-Mar-2009 Sarah Parker 0.1.0.1 Minor amendment in response to customer request

05-Mar-2009 Mick Harney 0.2.0.0 Raised to Baseline Candidate #2

16-Mar-2009 Mick Harney 1.0.0.0 Raised to Baseline

Document Status has the following meaning:

Drafts 0.0.0.X - Draft document reviewed by the Microsoft CUI Project team and the

Authority designate for the appropriate Project. The document is liable to change.

Working Baseline 0.0.X.0 - The document has reached the end of the review phase and

may only have minor changes. The document will be submitted to the Authority CUI Project team for wider review by stakeholders, ensuring buy-in and to assist in communication.

Baseline Candidate 0.X.0.0 - The document has reached the end of the review phase and

it is ready to be frozen on formal agreement between the Authority and the Company

Baseline X.0.0.0 - The document has been formally agreed between the Authority and the

Company

Note that minor updates or corrections to a document may lead to multiple versions at a particular status.

Open Issues Summary

None

Page 88

HSCIC Controlled Document

Audience

The audience for this document includes:

Authority CUI Manager / Project Sponsor . Overall project manager and sponsor for the

NHS CUI project within the Authority.

Authority Clinical Applications and Patient Safety Project Project Manager.

Responsible for ongoing management and administration of the Project.

The Authority Project Team . This document defines the approach to be taken during this

assessment and therefore must be agreed by the Authority.

Microsoft NHS CUI Team . This document defines the approach to be taken during this

assessment, including a redefinition of the Clinical Applications and Patient Safety Project strategy.

Reviewers

Mike Carey Workstream Lead

Tim Chearman UX Architect

Peter Johnson Clinical Architect

Ann Slee Clinical Lead for e-Prescribing

Beverley Scott Clinical Safety Advisor

Dee Hackett Clinical Advisor

Frank Cross Clinical Advisor

Jasdeep Gill Clinical Advisor

Distribution

Mike Carey Workstream Lead

Tim Chearman UX Architect

Peter Johnson Clinical Architect

Ann Slee Clinical Lead for e-Prescribing

Beverley Scott Clinical Safety Advisor

Dee Hackett Clinical Advisor

Frank Cross Clinical Advisor

Jasdeep Gill Clinical Adviser

Page 89

HSCIC Controlled Document

Document Properties

Document Title Medications Management – Medications List User Interface Design Guidance

Author Clinical Applications and Patient Safety Project

Restrictions RESTRICTED – COMMERCIAL; MICROSOFT COMMERCIAL; Access restricted to: NHS CUI Project Team, Microsoft NHS Account Team

Creation Date 10 October 2008

Last Updated 23 June 2015

Copyright:

You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence or email psi@nationalarchives.gsi.gov.uk.

Page 90